

[19] Patents Registry [11] 1258574 B  
The Hong Kong Special Administrative Region  
香港特別行政區  
專利註冊處

[12] **STANDARD PATENT (R) SPECIFICATION**  
**轉錄標準專利說明書**

[21] Application no. 申請編號 [51] Int. Cl.  
19100929.5 A61K 35/74 (2015.01) A61P 1/14 (2006.01)  
[22] Date of filing 提交日期 [51] A61P 29/00 (2006.01)  
18.01.2019

---

[54] COMPOSITIONS COMPRISING BACTERIAL STRAINS  
包含細菌菌株的組合物

[60] Divisional application no.& receipt date 分開申請編號及收 件日期 42020001391.0 14.01.2020	[73] Proprietor 專利所有人 4D PHARMA PLC 5th floor, 9 Bond Court Leeds, LS1 2JZ UNITED KINGDOM
[30] Priority 優先權 12.12.2016 GB 1621123.7	[72] Inventor 發明人 JEFFERY, Ian SHANAHAN, Fergus O'TOOLE, Paul STEVENSON, Alex MULDER, Imke SAVIGNAC, Helene
[43] Date of publication of application 申請發表日期 15.11.2019	[74] Agent and / or address for service 代理人及/或送達地址 DEACONS 5th Floor, Alexandra House Central HONG KONG
[45] Date of publication of grant of patent 批予專利的發表日期 17.07.2020	
[86] International application no. 國際申請編號 PCT/GB2017/053722	
[87] International publication no. and date 國際申請發表編號及 日期 WO2018/109461 21.06.2018	
EP Application no. & date 歐洲專利申請編號及日期 EP 17818220.0 12.12.2017	
EP Publication no. & date 歐洲專利申請發表編號及日期 EP 3359172 15.08.2018	
Date of grant in designated patent office 指定專利當局批予專利日 期 12.06.2019	



(11)

EP 3 359 172 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:  
**12.06.2019 Bulletin 2019/24**

(51) Int Cl.:  
**A61K 35/74 (2015.01)** **A61P 1/14 (2006.01)**  
**A61P 29/00 (2006.01)**

(21) Application number: **17818220.0**(86) International application number:  
**PCT/GB2017/053722**(22) Date of filing: **12.12.2017**(87) International publication number:  
**WO 2018/109461 (21.06.2018 Gazette 2018/25)**(54) **COMPOSITIONS COMPRISING BACTERIAL STRAINS**

ZUSAMMENSETZUNGEN MIT BAKTERIENSTÄMMEN

COMPOSITIONS COMPRENANT DES SOUCHES BACTÉRIENNES

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

Designated Validation States:

**MA MD TN**(30) Priority: **12.12.2016 GB 201621123**(43) Date of publication of application:  
**15.08.2018 Bulletin 2018/33**(60) Divisional application:  
**19161691.1**(73) Proprietor: **4D PHARMA PLC  
Leeds, LS1 2JZ (GB)**

(72) Inventors:

- **JEFFERY, Ian  
Cork (IE)**
- **SHANAHAN, Fergus  
Kinsale,  
County Cork (IE)**
- **O'TOOLE, Paul  
Cork (IE)**
- **STEVENSON, Alex  
Leeds,  
Yorkshire LS1 2JZ (GB)**
- **MULDER, Imke  
Aberdeen,  
Aberdeenshire AB25 2ZS (GB)**

- **SAVIGNAC, Helene  
Leeds,  
Yorkshire LS1 2JZ (GB)**

(74) Representative: **Marshall, Cameron John  
Carpmaels & Ransford LLP  
One Southampton Row  
London WC1B 5HA (GB)**

(56) References cited:  
**WO-A1-2016/086161 WO-A1-2016/203218  
WO-A1-2017/148596 WO-A1-2018/011594  
WO-A2-2012/024638 US-A1- 2010 316 617**

- **4d Pharma Plc: "Clinical Update - RNS - London Stock Exchange", , 19 July 2016 (2016-07-19), XP055446737, Retrieved from the Internet:  
URL:<http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/DDDD/12896979.html> [retrieved on 2018-02-01]**
- **Anonymous: "4D pharma's Blautix for Irritable Bowel Syndrome shows positive impact - pharmaceutical daily news", , 13 December 2016 (2016-12-13), XP055446748, Retrieved from the Internet:  
URL:<http://www.pharmaceuticaldaily.com/4d-pharmas-blautix-for-irritable-bowel-syndrome-shows-positive-impact/> [retrieved on 2018-02-01]**
- **HARPER ASHTON ET AL: "The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome.", 26 January 2018 (2018-01-26), FOODS (BASEL, SWITZERLAND) 26 JAN 2018, VOL. 7, NR. 2 ISSN: 2304-8158**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- Catherine A. Lozupone ET AL: "Diversity, stability and resilience of the human gut microbiota", *Nature*, vol. 489, no. 7415, 1 September 2012 (2012-09-01), pages 220-230, XP055499616, GB ISSN: 0028-0836, DOI: 10.1038/nature11550

**Description****TECHNICAL FIELD**

5 [0001] This invention is in the field of compositions comprising bacterial strains isolated from the mammalian digestive tract and the use of such compositions in the treatment of disease, as defined in the claims.

**BACKGROUND TO THE INVENTION**

10 [0002] The human intestine is thought to be sterile *in utero*, but it is exposed to a large variety of maternal and environmental microbes immediately after birth. Thereafter, a dynamic period of microbial colonization and succession occurs, which is influenced by factors such as delivery mode, environment, diet and host genotype, all of which impact upon the composition of the gut microbiota, particularly during early life. Subsequently, the microbiota stabilizes and becomes adult-like [1]. The human gut microbiota contains more than 1500 different phylotypes dominated in abundance 15 levels by two major bacterial divisions (*phyla*), the Bacteroidetes and the Firmicutes [2]. The successful symbiotic relationships arising from bacterial colonization of the human gut have yielded a wide variety of metabolic, structural, protective and other beneficial functions. The enhanced metabolic activities of the colonized gut ensure that otherwise indigestible dietary components are degraded with release of by-products providing an important nutrient source for the host and additional health benefits. Similarly, the immunological importance of the gut microbiota is well-recognized and is exemplified in germfree animals which have an impaired immune system that is functionally reconstituted following the 20 introduction of commensal bacteria [3-5].

[0003] Dramatic changes in microbiota composition have been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, the levels of *Clostridium* cluster XIVa bacteria are reduced in IBD subjects whilst numbers of *E. coli* are increased, suggesting a shift in the balance of symbionts and pathobionts within 25 the gut [6-9, 18].

[0004] In recognition of the potential positive effect that certain bacterial strains may have on the animal gut, various strains have been proposed for use in the treatment of various diseases (see, for example, [10-13]). A number of strains, including mostly *Lactobacillus* and *Bifidobacterium* strains, have been proposed for use in treating various bowel disorders (see [14] for a review and see [15]). Reference [16] proposes the use of strains of the genus *Blautia* for use in modulating the microbial balance of the digestive ecosystem. In the context of reference 16, modulation refers to promoting the activity of the acetogenic bacterial flora to the detriment of methanogenic and sulfur reducing bacteria. This document therefore teaches only an increase in acetogenic bacteria. There is no discussion relating to the diversity of species belonging to a number of taxa. Reference [17] discusses the use of *Blautia* for improving survival in patients affected by graft versus host disease (GVHD). It mentions that increased bacterial diversity is associated with reduced GVHD-related mortality and that increased amounts of bacteria of the *Blautia* genus were associated with reduced GVHD. However, there is no suggestion that the administration of *Blautia* to a patient effects an increase in microbiota diversity and/or induces stability of the microbiota in a subject.

[0005] The relationship between different bacterial strains and different diseases, and the precise effects of particular bacterial strains on the gut and at a systemic level and on any particular types of diseases, are poorly characterised and 40 results to date are variable and pose more questions than provide answers [18].

[0006] A hallmark of many human diseases linked to microbiota alteration is loss of microbiota diversity. As distinct from so-called *dysbiosis* which is simply an altered microbiota composition compared to the typical aggregate microbiota in healthy subjects, loss of microbiota diversity may be quantified by a measurable reduction in number of the sequence-based bacterial classifications or Operational Taxonomic Units (OTUs) in a sample, typically determined by 16S rRNA 45 amplicon sequencing methods. Loss of diversity is also measured by reductions in the Shannon Diversity Index, or the Chao index. Reduced microbiota diversity is reported in recent studies of obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), type 2 diabetes and frail older people [20]. Reestablishing the healthy microbiota can be difficult as the bacteria in the gut are resistant to colonisation. This poses a challenge when trying to treat the microbiota of unhealthy subjects by increasing the diversity of the microbiota [19]. The accompanying loss of microbial metabolic 50 function is assumed to be a contributory factor to the symptoms of these pathophysiologies. In contrast to healthy adults in whom the microbiota is stable, the microbiota of unhealthy subjects such as those suffering IBD, IBS and frail elderly subjects is unstable [18, 20].

[0007] There is a requirement for the potential effects of gut bacteria to be characterised so that new therapies using 55 gut bacteria can be developed.

**SUMMARY OF THE INVENTION**

[0008] The inventors have developed new therapies for treating and preventing diseases and disorders by increasing

or maintaining the intestinal microbiota diversity in a subject. In particular, the inventors have identified that bacterial strains from the genus *Blautia* can be effective in increasing or maintaining the number and/or evenness of different types of bacteria in the distal gut of a subject. As described in the examples, oral administration of compositions comprising *Blautia hydrogenotrophica* increases the microbiota diversity in stool. This increase in diversity was seen in healthy and IBS subjects. However, IBS subjects receiving placebo had a statistically significant reduction in microbiome diversity during the course of the study. Additionally, the examples show that treatment with compositions comprising *Blautia hydrogenotrophica*, but not placebo, increased the stability of the microbiota in IBS subjects throughout the course of the study. The stability of the microbiota in subjects receiving the composition comprising *Blautia hydrogenotrophica* was comparable to that of healthy control subjects.

[0009] Therefore, in a first embodiment, the invention provides a composition comprising a bacterial strain of the species *Blautia hydrogenotrophica*, for use in treating or preventing irritable bowel syndrome wherein the treatment or prevention comprises increasing the microbiota diversity in the subject.

[0010] The term "increasing or maintaining the microbiota diversity" is used herein to mean increasing or maintaining the number of different types of bacteria and/or the evenness of the different types of bacteria in the microbiota of a subject. The microbiota diversity is increased. In some embodiments, the number of different genera of bacteria in the microbiota is increased. In some embodiments, the number of different species of bacteria in the microbiota is increased. In some embodiments, the number of different strains of bacteria in the microbiota is increased. In some embodiments, the microbiota diversity is maintained. In some embodiments, the number of different genera of bacteria in the microbiota is maintained. In some embodiments, the number of different species of bacteria in the microbiota is maintained. In some embodiments, the number of different strains of bacteria in the microbiota is maintained. In some embodiments, the number of genera, species and strains in the microbiota is increased or maintained.

[0011] The increase in microbiota diversity may be for non-acetogenic bacteria. It may also be for both acetogenic and non-acetogenic bacteria. Such bacteria are well known in the art. Briefly, acetogenic bacteria produce acetate as an end product of anaerobic respiration or fermentation.

[0012] In some embodiments, loss, increase or maintenance of microbiota diversity may be quantified by a measurable reduction, increase or maintenance, respectively, in the number of the sequence-based bacterial classifications or Operational Taxonomic Units (OTUs) in a sample, typically determined by 16S rRNA amplicon sequencing methods. In some embodiments, loss of diversity may be measured by reductions in the Shannon Diversity Index, or the Chao index. Conversely, in some embodiments, an increase of diversity may be measured by an increase in the Shannon Diversity Index, or the Chao index. Similarly, in some embodiments, maintenance of diversity may be measured by the same result in the Shannon Diversity Index, or the Chao index.

[0013] In some embodiments, the evenness of the different types of bacteria is increased. In some embodiments, the relative abundance of the different types of bacteria in the microbiota becomes more even following treatment or prevention with a composition of the invention.

[0014] The inventors have also developed new therapies for treating and preventing diseases and disorders by inducing stability of the intestinal microbiota. In particular, the inventors have identified that bacterial strains from the genus *Blautia* induce stability of the intestinal microbiota. By "induce stability" is meant that the microbiota diversity remains stable and also the relative numbers of the different Genus in the microbiota remains stable. This is important as a number of diseases and disorders, including IBS and IBD, are characterised by reduced stability of the microbiota. As described in the examples, oral administration of compositions comprising *Blautia hydrogenotrophica* induces stability of the microbiota in stool. Therefore, in a further embodiment, the disclosure provides a composition comprising a bacterial strain of the genus *Blautia*, for use in a method of inducing stability of the microbiota in a subject. Similarly, there is also provided a method of inducing stability of the microbiota in a subject comprising use of a bacterial strain of the genus *Blautia*.

[0015] In some embodiments of the disclosure, the relative numbers of the different bacterial species in the microbiota of a subject becomes more stable following treatment or prevention with a composition of the disclosure, for example in a subject diagnosed with a disease or disorder characterised by a reduction in the diversity of microbiota. In some embodiments of the disclosure, the relative numbers of the different bacterial Genus in the microbiota of a subject becomes more stable following treatment or prevention with a composition of the disclosure, for example in a subject diagnosed with a disease or disorder characterised by a reduction in the diversity of microbiota. The stability of a subject's microbiota can be assessed by comparing the microbiome from the subject at two different time points. If there is a difference in the microbiome, this can be indicative of disease or of a disorder being present. In some embodiments, the two different time points are at least three days apart (e.g. at least 1 week, 2 weeks, 1 month, 3 months, 6 months, 1 year, 2 years apart). In some embodiments, the two different time points are 3-7 days apart, 1-2 weeks apart, 2-4 weeks apart, 4-8 weeks apart, 8-24 weeks apart, 24-40 weeks apart, 40-52 weeks apart or more than 52 weeks apart. In some embodiments, more than two different time points are used, e.g. three, four, five or more than five time points. Suitable intervals are chosen between the various time points, for example, as set out above.

[0016] The bacterial strain is of *Blautia hydrogenotrophica* and is preferably the bacterium deposited under accession number DSM 10507/14294.

[0017] In some embodiments, the microbiota diversity refers to the microbiota diversity in stool in the subject. In some embodiments, the microbiota diversity refers to the microbiota diversity in a stool sample from the subject. In some embodiments, the microbiota diversity refers to the microbiota diversity in the distal gut of the subject. In some embodiments, the microbiota diversity refers to the microbiota diversity in the gastrointestinal tract of the subject. In some embodiments, the microbiota diversity to the microbiota diversity in the caecum. In some embodiments, the microbiota diversity refers to the microbiota diversity in the colon.

[0018] The invention provides a composition comprising a bacterial strain of the species *Blautia hydrogenotrophica*, for use in a method of treating or preventing irritable bowel syndrome wherein the treatment or prevention comprises increasing the microbiota diversity. In some embodiments, the treatment or prevention using a composition of the invention results in the microbiota diversity increasing to the levels present in a healthy individual. In some embodiments, treatment or prevention using a composition of the invention results in the microbiota diversity increasing to levels greater than those present in some healthy individuals. In some embodiments, the healthy individual is of a similar/same age to the subject and/or is of a similar/same race to the subject. Similarly, the invention also provides a method of treatment or prevention of a disease or disorder associated with a level of microbiota diversity that is reduced relative to the microbiota diversity of a healthy subject wherein the method comprises administering a composition comprising a bacterial strain of the genus *Blautia*. Examples of diseases or disorders associated with a reduced level of microbiota diversity include but are not limited to: IBS, IBD [21], obesity [22], type 2 diabetes, infectious diseases, allergic diseases, autoimmune diseases and metabolic diseases/disorders. Treatment or prevention of these diseases and disorders is encompassed by the invention. In some embodiments, the disease or disorder is IBS.

[0019] In some embodiments, the subject is an infant or child with a reduced microbiota diversity compared to a healthy infant or child, respectively. It has been observed that some children who develop an allergic disease later in life have a reduced diversity of faecal microbiota as 1 week old infants [23]. Thus, in some embodiments, the infant is less than 1 week old, is less than 2 weeks old, is less than one month old, is less than two months old or is less than four months old. In some embodiments, the subject is an infant who has not been delivered via a vaginal birth. For example, in some embodiments, the subject is an infant who has been delivered by Caesarean section. Reduced microbiota diversity has also been reported in frail elderly subjects. In some embodiments, therefore, the subject is an elderly subject, for example, a frail elderly subject. In some embodiments, the subject is 65 or more years in age (e.g. 70 or more, 75 or more, 80 or more, 85 or more or 90 or more years in age) [20].

[0020] It has been estimated that a single human individual has approximately 101 different bacterial species and 195 different strains in its microbiota [24]. Accordingly, in some embodiments, the composition is for use in treating a subject having less than 101 different bacterial species (e.g. less than 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75 or 70 bacterial species) and/or less than 195 different strains (e.g. less than 194, 193, 192, 191, 190, 189, 188, 187, 186, 185, 183, 180, 175, 170, 165, 160, 150, 140 bacterial strains) in its microbiota. In some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 80 bacterial species (e.g. more than 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 bacterial species) or to 101 bacterial species. For example, in some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 90 bacterial species. For example, in some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 95 bacterial species. For example, in some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 97 bacterial species. For example, in some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 99 bacterial species. In some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 160 bacterial strains (e.g. more than 165, 170, 185, 186, 187, 188, 189, 190, 191, 192, 193 or 194 bacterial species) or to 195 bacterial strains. For example, in some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 175 bacterial strains. For example, in some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 185 bacterial strains. For example, in some embodiments, the treatment or prevention results in the microbiota diversity increasing to more than 190 bacterial strains.

[0021] In some embodiments, the treatment or prevention results in the microbiota diversity increasing by at least one bacterial genus (e.g. by at least two, three, four, five, six, seven, eight, nine or ten bacterial genera). In some embodiments, the treatment or prevention results in the microbiota diversity increasing by at least one bacterial species (e.g. by at least two, three, four, five, six, seven, eight, nine, ten, 12, 15, 17 or 20 bacterial species). In some embodiments, the treatment or prevention results in the microbiota diversity increasing by at least one bacterial strain (e.g. by at least two, three, four, five, six, seven, eight, nine, ten, 12, 15, 17, 20 or 25 bacterial strains).

[0022] In some embodiments, the disclosure provides a composition comprising a bacterial strain of the genus *Blautia*, for use in a method of treating or preventing a disease or disorder associated with reduced stability of the microbiota compared to the stability of the microbiota in a healthy subject (or compared to a population of healthy subjects). By "reduced stability of the microbiota" is meant that the microbiota diversity does not remain as stable and also the relative numbers of the different Genus in the microbiota do not remain as stable as the stability observed in a healthy subject or in a population of healthy subjects. In some embodiments, inducing stability of the microbiota results in the stability

being induced to a similar level as is present in a healthy subject, or in a population of healthy subjects. In some embodiments, inducing stability of the microbiota results in the stability being induced to the same level as is present in a healthy subject, or in a population of healthy subjects. Similarly, the disclosure provides a method of treating or preventing a disease or disorder associated with reduced stability of the microbiota wherein the method comprises 5 administering a composition comprising a bacteria strain of the genus *Blautia*. For example, the pathogenesis of some diseases or disorders is characterised by reduced stability of the microbiota. Examples of such diseases and disorders are IBS, IBD, diabetes (e.g. type 2 diabetes), allergic diseases, autoimmune diseases and metabolic diseases/disorders. Accordingly, in some embodiments, the disclosure provides a composition comprising a bacterial strain of the genus 10 *Blautia*, for use in a method of treating or preventing a disease or disorder associated with reduced stability of the microbiota, wherein the treatment or prevention comprises inducing stability of the microbiota. In some embodiments, the disease or disorder is selected from IBS, IBD, diabetes (e.g. type 2 diabetes), allergic diseases, autoimmune diseases and metabolic diseases/disorders. In some embodiments, the disease or disorder is IBS or IBD. In some embodiments, the disease or disorder is IBS. Accordingly, in some embodiments, the disclosure provides a composition comprising a bacterial strain of the genus *Blautia*, for use in a method of treating or preventing IBS or IBD, wherein the treatment or 15 prevention comprises inducing stability of the microbiota.

**[0023]** In some embodiments, the invention provides a composition comprising a bacterial strain of the species *Blautia hydrogenotrophica*, for use in treating or preventing irritable bowel syndrome wherein the treatment or prevention comprises increasing the microbiota diversity in the subject further comprising diagnosing a subject as having a reduced level of microbiota diversity and then if a reduced level of diversity is found to be present, administering a composition 20 comprising a bacterial strain of the genus *Blautia hydrogenotrophica* to the subject.

**[0024]** In some embodiments, the disclosure provides a method of treatment or prevention of a disease or disorder associated with reduced stability of microbiota relative to the stability of microbiota in a healthy subject wherein the method comprises diagnosing a subject as having reduced stability of microbiota and then if reduced stability is found to be present, administering a composition comprising a bacterial strain of the genus *Blautia* to the subject.

**[0025]** The bacterial strain in the composition is of *Blautia hydrogenotrophica*. Closely related strains have a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Blautia hydrogenotrophica*. The bacterial strain may have a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5. Preferably, the bacterial strain has the 16s rRNA sequence of SEQ ID NO:5. Most preferably, the bacterial strain in the composition is the *Blautia hydrogenotrophica* strain deposited under accession 30 number DSM 10507/14294.

**[0026]** In certain embodiments, the composition of the invention is for oral administration. Oral administration of the strains of the invention can be effective for increasing the microbiota diversity and/or inducing the stability of the microbiota. Also, oral administration is convenient for subjects and practitioners and allows delivery to and / or partial or total colonisation of the intestine.

**[0027]** In certain embodiments, the composition of the invention comprises one or more pharmaceutically acceptable excipients or carriers.

**[0028]** In certain embodiments, the composition of the invention comprises a bacterial strain that has been lyophilised. Lyophilisation is an effective and convenient technique for preparing stable compositions that allow delivery of bacteria, and is shown to provide effective compositions in the examples.

**[0029]** In certain embodiments, the invention provides a food product comprising the composition as defined in the claims.

**[0030]** In certain embodiments, the invention provides a vaccine composition comprising the composition as defined in the claims.

#### 45 BRIEF DESCRIPTION OF DRAWINGS

**[0031]**

**Figure 1:** Comparison of microbiota in healthy and IBS patients.

**Figure 2:** Comparison of microbiota diversity between Day 16 and Day 1 for healthy and IBS patients after treatment with BlautiX or placebo.

**Figure 3:** A) Interconnectivity of the microbiome in healthy patients at Day 1, Day 16 and end of study after BlautiX treatment, B) Interconnectivity of the microbiome in IBS patients at Day 1, Day 16 and end of study after BlautiX treatment. The interconnectivity results seen on Day 1, Day 16 and at the End of Study for healthy individuals that are presented in Figure 3A are also shown in Figures 3A1, 3A2 and 3A3, respectively. The interconnectivity results seen on Day 1, Day 16 and at the End of Study for IBS patients that are presented in Figure 3B are also shown in

Figures 3B1, 3B2 and 3B3, respectively.

**Figure 4:** A comparison of the instability in microbiota profiles in healthy and IBS patients after treatment with BlautiX or placebos at A) Day 16 and Day 1, B) end of study and Day 1 and C) end of study and Day 16.

**Figure 5:** Comparison of microbiota diversity at different time points for healthy and IBS patients after BlautiX treatment.

**Figure 6:** A) The mutual exclusion network in healthy patients at Day 1, Day 16 and end of study after BlautiX treatment. B) The mutual exclusion network in IBS patients at Day 1, Day 16 and end of study after BlautiX treatment. The mutual exclusion results seen on Day 1, Day 16 and at the End of Study for healthy individuals that are presented in Figure 6A are also shown in Figures 6A1, 6A2 and 6A3, respectively. The mutual exclusion results seen on Day 1, Day 16 and at the End of Study for IBS patients that are presented in Figure 6B are also shown in Figures 6B1, 6B2 and 6B3, respectively.

**Figure 7:** Hierarchical clustering of microbiota.

**Figure 8:** Comparison of microbiota profiles before (D14) and after (D32) Blautix treatment based on Bray-Curtis dissimilarities.

**Figure 9:** (A) Visualization of microbiota profiles of different groups at D-14 using PCoA based on Bray-Curtis dissimilarities. (B) Visualization of microbiota profiles of the groups at D14 using PCoA based on Bray-Curtis dissimilarities. (C) Significant difference (p-value=0.002) in the microbiota profiles for the Blautix group was seen across the timepoints.

**Figure 10:** Comparison of microbiota profiles for Blautix treatment at study timepoints (D-14, D-1, D34) based on Bray-Curtis dissimilarities.

## DISCLOSURE OF THE INVENTION

### ***Bacterial strains***

**[0032]** The compositions for use according to the invention comprise a bacterial strain of the genus *Blautia hydrogenotrophica*. The examples demonstrate that bacteria of this species are useful for increasing the microbiota diversity and/or inducing the stability of the microbiota. Most preferred is the bacterium deposited under accession number DSM 10507/14294.

**[0033]** The *Blautia* species are Gram-reaction-positive, non-motile bacteria that may be either coccoid or oval and all are obligate anaerobes that produce acetic acid as the major end product of glucose fermentation [25]. *Blautia* may be isolated from the human gut, although *B. producta* was isolated from a septicaemia sample.

**[0034]** *Blautia hydrogenotrophica* (previously known as *Ruminococcus hydrogenotrophicus*) has been isolated from the guts of mammals, is strictly anaerobic, and metabolises H<sub>2</sub>/CO<sub>2</sub> to acetate, which may be important for human nutrition and health. The type strain of *Blautia hydrogenotrophica* is S5a33 = DSM 10507 = JCM 14656. The GenBank accession number for the 16S rRNA gene sequence of *Blautia hydrogenotrophica* strain S5a36 is X95624.1 (disclosed herein as SEQ ID NO:5). This exemplary *Blautia hydrogenotrophica* strain is described in [25] and [26]. The S5a33 strain and the S5a36 strain correspond to two subclones of an acetogenic strain isolated from a faecal sample of a healthy subject. They show identical morphology, physiology and metabolism and have identical 16S rRNA sequences. Thus, in some embodiments, the *Blautia hydrogenotrophica* for use in the invention has the 16S rRNA sequence of SEQ ID NO:5.

**[0035]** The *Blautia hydrogenotrophica* bacterium deposited under accession number DSM 10507 and also under accession number DSM 14294 was tested in the examples and is also referred to herein as strain BH. Strain BH was deposited with the Deutsche Sammlung von Mikroorganismen [German Microorganism Collection] (Mascheroder Weg 1b, 38124 Braunschweig, Germany) on 10th May 2001 as "*Ruminococcus hydrogenotrophicus*" under accession number DSM 10507 and also under accession number DSM 14294. The depositor was INRA Laboratoire de Microbiologie CR de Clermont-Ferrand/Theix 63122 Saint Genes Champanelle, France. Ownership of the bacterium deposited as DSM 10507 and DSM 14294 has passed via assignment to 4D Pharma Plc.

**[0036]** Bacterial strains closely related to the strain tested in the examples are also expected to be effective for increasing the microbiota diversity and/or inducing the stability of the microbiota. In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Blautia hydrogenotrophica*. Preferably, the bacterial strain for use in the

invention has a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5. Preferably, the bacterial strain for use in the invention has a 16s rRNA sequence that has the sequence of SEQ ID NO:5.

[0037] *Blautia hydrogenotrophica* strains that are biotypes of the bacterium deposited under accession number DSM 10507/14294 are also expected to be effective for increasing the microbiota diversity and/or inducing the stability of the microbiota. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.

[0038] Strains that are biotypes of a bacterium deposited under accession number DSM 10507/14294 and that are suitable for use in the invention may be identified by sequencing other nucleotide sequences for a bacterium deposited under accession number DSM 10507/14294. For example, substantially the whole genome may be sequenced and a biotype strain for use in the invention may have at least 97%, 98%, 99%, 99.5% or 99.9% sequence identity across at least 80% of its whole genome (e.g. across at least 85%, 90%, 95% or 99%, or across its whole genome). For example, in some embodiments, a biotype strain has at least 98% sequence identity across at least 98% of its genome or at least 99% sequence identity across 99% of its genome. Other suitable sequences for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)<sub>5</sub>, or REP or [28]. Biotype strains may have sequences with at least 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of a bacterium deposited under accession number DSM 10507/14294. In some embodiments, a biotype strain has a sequence with at least 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294 and comprises a 16S rRNA sequence that is at least 99% identical (e.g. at least 99.5% or at least 99.9% identical) to SEQ ID NO:5. In some embodiments, a biotype strain has a sequence with at least 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294 and has the 16S rRNA sequence of SEQ ID NO:5.

[0039] Alternatively, strains that are biotypes of a bacterium deposited under accession number DSM 10507/14294 and that are suitable for use in the invention may be identified by using the accession number DSM 10507/14294 deposit and restriction fragment analysis and/or PCR analysis, for example by using fluorescent amplified fragment length polymorphism (FAFLP) and repetitive DNA element (rep)-PCR fingerprinting, or protein profiling, or partial 16S or 23s rDNA sequencing. In preferred embodiments, such techniques may be used to identify other *Blautia hydrogenotrophica* strains.

[0040] In certain embodiments, strains that are biotypes of a bacterium deposited under accession number DSM 10507/14294 and that are suitable for use in the invention are strains that provide the same pattern as a bacterium deposited under accession number DSM 10507/14294 when analysed by amplified ribosomal DNA restriction analysis (ARDRA), for example when using Sau3AI restriction enzyme (for exemplary methods and guidance see, for example, [29]). Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as a bacterium deposited under accession number DSM 10507/14294.

[0041] Other *Blautia hydrogenotrophica* strains that are useful in the compositions and methods of the invention, such as biotypes of a bacterium deposited under accession number DSM 10507/14294, may be identified using any appropriate method or strategy, including the assays described in the examples. For instance, strains for use in the invention may be identified by culturing bacteria and administering to rats to test in the distension assay. In particular, bacterial strains that have similar growth patterns, metabolic type and/or surface antigens to a bacterium deposited under accession number DSM 10507/14294 may be useful in the invention. A useful strain will have comparable microbiota modulatory activity to the DSM 10507/14294 strain. In particular, a biotype strain will elicit comparable effects on the microbiota to the effects shown in the Examples, which may be identified by using the culturing and administration protocols described in the Examples.

[0042] A particularly preferred strain of the invention is the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294. This is the exemplary BH strain tested in the examples and shown to be effective for increasing the microbiota diversity and/or inducing the stability of the microbiota. Therefore, the invention provides a cell, such as an isolated cell, of the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294, or a derivative thereof, for use in therapy, in particular for the diseases and disorders described herein.

[0043] A derivative of the strain deposited under accession number DSM 10507/14294 may be a daughter strain (progeny) or a strain cultured (subcloned) from the original. A derivative of a strain of the invention may be modified, for example at the genetic level, without ablating the biological activity. In particular, a derivative strain of the invention is therapeutically active. A derivative strain will have comparable microbiota modulatory activity to the original DSM 10507/14294 strain. In particular, a derivative strain will elicit comparable effects on the microbiota to the effects shown in the Examples, which may be identified by using the culturing and administration protocols described in the Examples. A derivative of the DSM 10507/14294 strain will generally be a biotype of the DSM 10507/14294 strain.

[0044] References to cells of the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294 encompass any cells that have the same safety and therapeutic efficacy characteristics as the strains deposited under accession number DSM 10507/14294, and such cells are encompassed by the invention.

[0045] In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonising the intestine.

**Therapeutic uses**

5

[0046] The compositions of the invention are for use in increasing the microbiota diversity, as defined in the claims. Reduced diversity of the microbiota is associated with numerous pathological diseases and disorders, and the examples demonstrate that the compositions of the invention may be effective for increasing the microbiota diversity. Accordingly, the disease or disorder to be treated or prevented using a composition of the invention is preferably a disease or disorder associated with a level of microbiota diversity that is reduced relative to the microbiota diversity of a healthy subject, as defined in the claims. Thus, in some embodiments, the disease or disorder may be associated with a level of microbiota diversity that is reduced relative to the microbiota diversity of a healthy subject and also be associated with reduced stability of the microbiota.

10

[0047] The compositions of the invention are for use in treating or preventing IBS. The treatment or prevention comprises increasing the microbiota diversity and/or inducing the stability of the microbiota in the subject.

15

[0048] In preferred embodiments, the compositions of the invention comprise the bacterium deposited under accession number DSM 10507/14294 and are for use in increasing the microbiota diversity in the subject in the treatment of IBS.

20

[0049] In certain embodiments, the compositions are for use in subjects that exhibit, or are expected to exhibit, reduced levels of microbiota diversity, for example, when compared to a healthy subject, or a population of healthy subjects. For example, in some embodiments, the composition is for use in treating a subject having less than 101 different bacterial species (e.g. less than 100, 99, 98, 97, 96, 95, 93, 90, 85, 80, 75 or 70 bacterial species) and/or less than 195 different strains (e.g. less than 193, 190, 187, 185, 183, 180, 175, 170, 165, 160, 150, 140 bacterial strains) in its microbiota. For example, in some embodiments, the composition is for use in treating a subject that has at least one bacterial genus (e.g. at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 bacterial genera) fewer in its intestinal microbiota compared to a healthy subject or compared to a population of healthy subjects. In some embodiments, the treatment or prevention comprises a step of diagnosing a subject as having a reduced level of microbiota diversity and then if a reduced level of diversity is found to be present, the subject is then treated with a composition according to the invention.

25

[0050] In certain embodiments, the subject is an infant. In certain embodiments, the subject is a child. In certain embodiments, the subject is an adult.

30

[0051] In certain embodiments, the subject is a healthy subject. For example, in some embodiments in which the composition is used for preventing a disease or disorder, the subject is a healthy subject, optionally one identified as being at risk of developing a disease or disorder characterised by a reduction in microbiota diversity.

35

[0052] In certain embodiments, the subject has previously received, is receiving, or will be receiving antibiotic treatment. Accordingly, in some embodiments, the treatment or prevention comprises administering the composition of the invention after, together with, or before antibiotic treatment. The composition of the invention and the one or more antibiotics may be for separate, simultaneous or sequential administration.

40

[0053] In some embodiments, the composition of the invention is for use in a method of increasing the microbiota diversity in a subject having an increased level of hydrogen in their breath relative to a healthy subject. In some embodiments, the composition of the invention is for use in reducing the hydrogen level in the breath of a subject exhibiting or who is expected to exhibit a reduced level of diversity of its microbiota. The subject is preferably a subject diagnosed as having IBS. Treatment with a composition of the invention reduces the level of hydrogen detected in hydrogen breath tests. Accordingly, the hydrogen levels are preferably assessed using a hydrogen breath test. The hydrogen breath test is well known in the art and so the skilled person will know how to conduct such a test. In some embodiments, the subject is administered lactulose as the substrate for the test.

45

[0054] The hydrogen breath test is also a useful tool for monitoring the effectiveness or likely effectiveness of increasing the microbiota diversity and of treatment or prevention using a composition of the invention. For example, a reduction in the level of hydrogen detected in a subject's breath following treatment with a composition of the invention may indicate that the treatment is having an increasing, stabilising, therapeutic or preventative effect. Accordingly, in some embodiments the uses of the invention further comprise monitoring the hydrogen level in a subject's breath during and/or following treatment with a composition of the invention and thereby assessing the effectiveness or likely effectiveness of increasing, stabilising, treatment or prevention. For example, hydrogen levels may be monitored at one or more (e.g. 1, 2, 3, 4 or more than 4) times, for example, including before treatment, at the start of treatment, during treatment, at the end of treatment and/or following treatment, as desired. In some embodiments, the level of hydrogen in the subject's breath at the end and/or following the dosing period (during which the composition is administered to the subject) is compared to the level at the start and/or before the dosing period and a reduction in the level indicates the effectiveness or likely effectiveness of the increasing, stabilising, treatment or prevention. For example, in embodiments in which the dosing period is 16 days, it may be desirable to take measurements at day 1 and day 16, or for example at day 1, day 2, day 15 and day 16. In some embodiments, multiple measurements are taken and the mean of those measurements

obtained (for example, the mean of day 1 and day 2 and the mean of day 15 and day 16). In some embodiments, a reduction in at least 40 ppm in the hydrogen level Cmax indicates that the increasing, stabilising, treatment or prevention is effective or likely to be effective. In some embodiments, the hydrogen level in the subject's breath is measured only once, for example, at the end of or following treatment, and the finding that the level is at or close to a predetermined level is indicative that the increasing stabilising, treatment or prevention is likely to have been effective. The hydrogen breath test is a standard assay and so predetermined levels are known in the art.

**[0055]** Treatment or prevention may refer to, for example, an alleviation of the severity of symptoms or a reduction in the frequency of exacerbations or the range of triggers that are a problem for the subject.

**[0056]** Bacteria in the microbiota may be detected in faeces from a subject, using standard techniques, such as the qPCR techniques used in the examples.

#### ***Modes of administration***

**[0057]** Preferably, the compositions of the invention are to be administered to the gastrointestinal tract in order to enable delivery to and / or partial or total colonisation of the intestine with the bacterial strain of the invention, as defined in the claims. Generally, the compositions of the invention are administered orally, but they may be administered rectally, intranasally, or via buccal or sublingual routes.

**[0058]** In certain embodiments, the compositions of the invention may be administered as a foam, as a spray or a gel.

**[0059]** In certain embodiments, the compositions of the invention may be administered as a suppository, such as a rectal suppository, for example in the form of a theobroma oil (cocoa butter), synthetic hard fat (e.g. supocire, witepsol), glycerol-gelatin, polyethylene glycol, or soap glycerin composition.

**[0060]** In certain embodiments, the composition of the invention is administered to the gastrointestinal tract via a tube, such as a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (J tube), percutaneous endoscopic gastrostomy (PEG), or a port, such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.

**[0061]** The compositions of the invention may be administered once, or they may be administered sequentially as part of a treatment regimen. In certain embodiments, the compositions of the invention are to be administered daily. The examples demonstrate that daily administration provides successful delivery and clinical benefits.

**[0062]** In certain embodiments, the compositions of the invention are administered regularly, such as daily, every two days, or weekly, for an extended period of time, such as for at least one week, two weeks, one month, two months, six months, or one year. The examples demonstrate that *B. hydrogenotrophica* administration may not result in permanent colonisation of the intestines, so regular administration for extended periods of time may provide greater therapeutic and/or prophylactic benefits.

**[0063]** In certain embodiments of the invention, treatment according to the invention is accompanied by assessment of the subject's gut microbiota. Treatment may be repeated if delivery of and / or partial or total colonisation with the strain of the invention is not achieved such that efficacy is not observed, or treatment may be ceased if delivery and / or partial or total colonisation is successful and efficacy is observed.

**[0064]** In certain embodiments, the composition of the invention may be administered to a pregnant animal, for example a mammal such as a human in order to prevent reduced levels of diversity in the microbiota and/or reduced stability of the microbiota developing in her child *in utero* and / or after it is born.

**[0065]** The compositions of the invention may be administered to a subject that has been diagnosed with reduced microbiota diversity relative to a healthy subject and/or reduced stability of the microbiota or a disease or disorder associated with reduced microbiota diversity relative to a healthy subject and/or reduced stability of the microbiota, or that has been identified as being at risk of reduced microbiota diversity relative to a healthy subject and/or reduced stability of the microbiota. The compositions may also be administered as a prophylactic measure to prevent the development of reduced microbiota diversity relative to a healthy subject and/or reduced stability of the microbiota in a healthy subject.

**[0066]** The compositions of the invention may be administered to a subject that has been identified as having an abnormal gut microbiota. For example, the subject may have reduced or absent colonisation by *Blautia*, and in particular *Blautia hydrogenotrophica*, *Blautia stercoris* or *Blautia wexlerae*.

**[0067]** The compositions of the invention may be administered as a food product, such as a nutritional supplement.

**[0068]** Generally, the compositions of the invention are for the treatment of humans, although they may be used to treat animals including monogastric mammals such as poultry, pigs, cats, dogs, horses or rabbits. The compositions of the invention may be useful for enhancing the growth and performance of animals. If administered to animals, oral gavage may be used.

**Compositions**

[0069] Generally, the composition of the invention comprises bacteria, as defined in the claims. In preferred embodiments of the invention, the composition is formulated in freeze-dried form. For example, the composition of the invention may comprise granules or gelatin capsules, for example hard gelatin capsules, comprising a bacterial strain of the invention.

[0070] Preferably, the composition of the invention comprises lyophilised bacteria. Lyophilisation of bacteria is a well-established procedure and relevant guidance is available in, for example, references [30-32]. The examples demonstrate that lyophilisate compositions are particularly effective.

[0071] Alternatively, the composition of the invention may comprise a live, active bacterial culture.

[0072] In some embodiments, the bacterial strain in the composition of the invention has not been inactivated, for example, has not been heat-inactivated. In some embodiments, the bacterial strain in the composition of the invention has not been killed, for example, has not been heat-killed. In some embodiments, the bacterial strain in the composition of the invention has not been attenuated, for example, has not been heat-attenuated. For example, in some embodiments, the bacterial strain in the composition of the invention has not been killed, inactivated and/or attenuated. For example, in some embodiments, the bacterial strain in the composition of the invention is live. For example, in some embodiments, the bacterial strain in the composition of the invention is viable. For example, in some embodiments, the bacterial strain in the composition of the invention is capable of partially or totally colonising the intestine. For example, in some embodiments, the bacterial strain in the composition of the invention is viable and capable of partially or totally colonising the intestine.

[0073] In some embodiments, the composition comprises a mixture of live bacterial strains and bacterial strains that have been killed.

[0074] In preferred embodiments, the composition of the invention is encapsulated to enable delivery of the bacterial strain to the intestine. Encapsulation protects the composition from degradation until delivery at the target location through, for example, rupturing with chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which may be triggered by changes in pH. Any appropriate encapsulation method may be used. Exemplary encapsulation techniques include entrapment within a porous matrix, attachment or adsorption on solid carrier surfaces, self-aggregation by flocculation or with cross-linking agents, and mechanical containment behind a microporous membrane or a microcapsule. Guidance on encapsulation that may be useful for preparing compositions of the invention is available in, for example, references [33] and [34].

[0075] The composition may be administered orally and may be in the form of a tablet, capsule or powder. Encapsulated products are preferred because *Blautia* are anaerobes. Other ingredients (such as vitamin C, for example), may be included as oxygen scavengers and prebiotic substrates to improve the delivery and / or partial or total colonisation and survival *in vivo*. Alternatively, the probiotic composition of the invention may be administered orally as a food or nutritional product, such as milk or whey based fermented dairy product, or as a pharmaceutical product.

[0076] The composition may be formulated as a probiotic.

[0077] A composition of the invention includes a therapeutically effective amount of a bacterial strain of the invention, as defined in the claims. A therapeutically effective amount of a bacterial strain is sufficient to exert a beneficial effect upon a subject. A therapeutically effective amount of a bacterial strain may be sufficient to result in delivery to and / or partial or total colonisation of the subject's intestine.

[0078] A suitable daily dose of the bacteria, for example for an adult human, may be from about  $1 \times 10^3$  to about  $1 \times 10^{11}$  colony forming units (CFU); for example, from about  $1 \times 10^7$  to about  $1 \times 10^{10}$  CFU; in another example from about  $1 \times 10^7$  to about  $1 \times 10^{11}$  CFU; in another example from about  $1 \times 10^8$  to about  $1 \times 10^{10}$  CFU; in another example from about  $1 \times 10^8$  to about  $1 \times 10^{11}$  CFU; in another example from about  $1 \times 10^6$  to about  $1 \times 10^{10}$  CFU.

[0079] In certain embodiments, the dose of the bacteria is at least  $10^9$  cells per day, such as at least  $10^{10}$ , at least  $10^{11}$ , or at least  $10^{12}$  cells per day.

[0080] In certain embodiments, the composition contains the bacterial strain in an amount of from about  $1 \times 10^6$  to about  $1 \times 10^{11}$  CFU/g, respect to the weight of the composition; for example, from about  $1 \times 10^8$  to about  $1 \times 10^{10}$  CFU/g. The dose may be, for example, 1 g, 3g, 5g, and 10g.

[0081] Typically, a probiotic, such as the composition of the invention, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually a non-digestible carbohydrate such as an oligo- or polysaccharide, or a sugar alcohol, which is not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalacto-oligosaccharides.

[0082] In certain embodiments, the probiotic composition of the present invention includes a prebiotic compound in an amount of from about 1 to about 30% by weight, respect to the total weight composition, (e.g. from 5 to 20% by weight). Carbohydrates may be selected from the group consisting of: fructo- oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomalt-oligosaccharides, pectins, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS), beta-glucans, arable gum modified and resistant starches, polydextrose, D-tagatose, acacia fibers,

carob, oats, and citrus fibers. In one aspect, the prebiotics are the short-chain fructo-oligosaccharides (for simplicity shown herein below as FOSs-c.c); said FOSs-c.c. are not digestible carbohydrates, generally obtained by the conversion of the beet sugar and including a saccharose molecule to which three glucose molecules are bonded.

**[0083]** The compositions of the invention may comprise pharmaceutically acceptable excipients or carriers. Examples of such suitable excipients may be found in the reference [35]. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in reference [36]. Examples of suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like. Examples of suitable diluents include ethanol, glycerol and water. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s). Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Preservatives, stabilizers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, cysteine and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used. A further example of a suitable carrier is saccharose. A further example of a preservative is cysteine.

**[0084]** The compositions of the invention may be formulated as a food product. For example, a food product may provide nutritional benefit in addition to the therapeutic effect of the invention, such as in a nutritional supplement. Similarly, a food product may be formulated to enhance the taste of the composition of the invention or to make the composition more attractive to consume by being more similar to a common food item, rather than to a pharmaceutical composition. In certain embodiments, the composition of the invention is formulated as a milk-based product. The term "milk-based product" means any liquid or semi-solid milk- or whey- based product having a varying fat content. The milk-based product can be, e.g., cow's milk, goat's milk, sheep's milk, skimmed milk, whole milk, milk recombined from powdered milk and whey without any processing, or a processed product, such as yoghurt, curdled milk, curd, sour milk, sour whole milk, butter milk and other sour milk products. Another important group includes milk beverages, such as whey beverages, fermented milks, condensed milks, infant or baby milks; flavoured milks, ice cream; milk-containing food such as sweets.

**[0085]** In certain embodiments, the compositions of the invention contain a single bacterial strain or species and do not contain any other bacterial strains or species. Such compositions may comprise only *de minimis* or biologically irrelevant amounts of other bacterial strains or species. Such compositions may be a culture or lyophilisate that is substantially free from other species of organism.

**[0086]** In certain embodiments, the compositions of the invention comprise one or more bacterial strains of the genus *Blautia*, and do not contain any other bacterial genus, or which comprise only *de minimis* or biologically irrelevant amounts of bacteria from another genus. In certain embodiments, the compositions of the invention comprise a single species of *Blautia hydrogenotrophica*, and do not contain any other bacterial species, or which comprise only *de minimis* or biologically irrelevant amounts of bacteria from another species. In certain embodiments, the compositions of the invention comprise a single strain of *Blautia hydrogenotrophica*, and do not contain any other bacterial strains or species, or which comprise only *de minimis* or biologically irrelevant amounts of bacteria from another strain or species.

**[0087]** In some embodiments, the compositions of the invention comprise more than one bacterial strain or species. For example, in some embodiments, the compositions of the invention comprise more than one strain from within the same species (e.g. more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 strains), and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise less than 50 strains from within the same species (e.g. less than 45, 40, 35, 30, 25, 20, 15, 12, 10, 9, 8, 7, 6, 5, 4 or 3 strains), and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise 1-40, 1-30, 1-20, 1-19, 1-18, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25, or 31-50 strains from within the same species and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise more than one species from within the same genus (e.g. more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 23, 25, 30, 35 or 40 species), and, optionally, do not contain bacteria from any other genus. In some embodiments, the compositions of the invention comprise less than 50 species from within the same genus (e.g. less than 50, 45, 40, 35, 30, 25, 20, 15, 12, 10, 8, 7, 6, 5, 4 or 3 species), and, optionally, do not contain bacteria from any other genus. In some embodiments, the compositions of the invention comprise 1-50, 1-40, 1-30, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25, or 31-50 species from within the same genus and, optionally, do not contain bacteria from any other genus. The invention comprises any combination of the foregoing.

**[0088]** In some embodiments, the composition comprises a *Blautia hydrogenotrophica* bacterial strain as part of a microbial consortium. For example, in some embodiments, the *Blautia* bacterial strain is present in combination with

one or more (e.g. at least 2, 3, 4, 5, 10, 15 or 20) other bacterial strains from other genera with which it can live symbiotically *in vivo* in the intestine. For example, in some embodiments, the composition comprises a bacterial strain of *Blautia hydrogenotrophica* in combination with a bacterial strain from a different genus. In some embodiments, the microbial consortium comprises two or more bacterial strains obtained from a faeces sample of a single organism, e.g. a human.

5 In some embodiments, the microbial consortium is not found together in nature. For example, in some embodiments, the microbial consortium comprises bacterial strains obtained from faeces samples of at least two different organisms. In some embodiments, the two different organisms are from the same species, e.g. two different humans. In some embodiments, the two different organisms are an infant human and an adult human. In some embodiments, the two different organisms are a human and a non-human mammal.

10 [0089] In some embodiments, the composition of the invention additionally comprises a bacterial strain that has the same safety and therapeutic efficacy characteristics as the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294, but which is not the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294, or which is not a *Blautia hydrogenotrophica* or which is not a *Blautia*.

15 [0090] In some embodiments in which the composition of the invention comprises more than one bacterial strain, species or genus, the individual bacterial strains, species or genera may be for separate, simultaneous or sequential administration. For example, the composition may comprise all of the more than one bacterial strain, species or genera, or the bacterial strains, species or genera may be stored separately and be administered separately, simultaneously or sequentially. In some embodiments, the more than one bacterial strains, species or genera are stored separately but are mixed together prior to use.

20 [0091] In some embodiments, the bacterial strain for use in the invention is obtained from human adult faeces. In some embodiments in which the composition of the invention comprises more than one bacterial strain, all of the bacterial strains are obtained from human adult faeces or if other bacterial strains are present they are present only in *de minimis* amounts. In some embodiments, the bacteria may have been cultured subsequent to being obtained from the human adult faeces and being used in a composition of the invention.

25 [0092] In some embodiments, the one or more *Blautia* bacterial strains is/are the only therapeutically active agent(s) in a composition of the invention. In some embodiments, the bacterial strain(s) in the composition is/are the only therapeutically active agent(s) in a composition of the invention.

[0093] The compositions for use in accordance with the invention may or may not require marketing approval.

30 [0094] In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilised. In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is spray dried. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is live. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is viable. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is capable of partially or totally colonising the intestine. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is viable and capable of partially or totally colonising the intestine.

35 [0095] In some cases, the lyophilised or spray dried bacterial strain is reconstituted prior to administration. In some cases, the reconstitution is by use of a diluent described herein.

40 [0096] The compositions of the invention can comprise pharmaceutically acceptable excipients, diluents or carriers.

[0097] In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain as used in the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to increase the microbiota diversity in a subject and/or induce stability of the microbiota and/or treat a disorder associated with reduced microbiota diversity and/or reduced stability of the microbiota when administered to a subject in need thereof, microbiota diversity, for example, a disease or disorder such as IBS, IBD, obesity, type 2 diabetes, one or more infectious diseases, one or more allergic diseases, one or more autoimmune diseases or one or more metabolic diseases/disorders.

45 [0098] In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about  $1 \times 10^3$  to about  $1 \times 10^{11}$  colony forming units per gram with respect to a weight of the composition.

50 [0099] In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of 1 g, 3 g, 5 g or 10 g.

[0100] In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal, and sub-lingual.

55 [0101] In certain embodiments, the invention provides the above pharmaceutical composition, comprising a carrier selected from the group consisting of lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol and sorbitol.

[0102] In certain embodiments, the invention provides the above pharmaceutical composition, comprising a diluent selected from the group consisting of ethanol, glycerol and water.

[0103] In certain embodiments, the invention provides the above pharmaceutical composition, comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweetener, acacia, tragacanth, sodium alginate, carboxymethyl cellulose, polyethylene glycol, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate and sodium chloride.

[0104] In certain embodiments, the invention provides the above pharmaceutical composition, further comprising at least one of a preservative, an antioxidant and a stabilizer.

[0105] In certain embodiments, the invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.

[0106] In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilised.

[0107] In certain embodiments, the invention provides the above pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is placed in an atmosphere having 50% relative humidity, at least 80% of the bacterial strain as measured in colony forming units, remains after a period of at least about: 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years.

[0108] In some embodiments, the composition of the invention is provided in a sealed container comprising a composition as described herein. In some embodiments, the sealed container is a sachet or bottle. In some embodiments, the composition of the invention is provided in a syringe comprising a composition as described herein.

[0109] The composition of the present invention may, in some embodiments, be provided as a pharmaceutical formulation. For example, the composition may be provided as a tablet or capsule. In some embodiments, the capsule is a gelatine capsule ("gel-cap").

[0110] In some embodiments, the compositions of the invention are administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.

[0111] Pharmaceutical formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.

[0112] In some embodiments the pharmaceutical formulation is an enteric formulation, i.e. a gastro-resistant formulation (for example, resistant to gastric pH) that is suitable for delivery of the composition of the invention to the intestine by oral administration. Enteric formulations may be particularly useful when the bacteria or another component of the composition is acid-sensitive, e.g. prone to degradation under gastric conditions.

[0113] In some embodiments, the enteric formulation comprises an enteric coating. In some embodiments, the formulation is an enteric-coated dosage form. For example, the formulation may be an enteric-coated tablet or an enteric-coated capsule, or the like. The enteric coating may be a conventional enteric coating, for example, a conventional coating for a tablet, capsule, or the like for oral delivery. The formulation may comprise a film coating, for example, a thin film layer of an enteric polymer, e.g. an acid-insoluble polymer.

[0114] In some embodiments, the enteric formulation is intrinsically enteric, for example, gastro-resistant without the need for an enteric coating. Thus, in some embodiments, the formulation is an enteric formulation that does not comprise an enteric coating. In some embodiments, the formulation is a capsule made from a thermogelling material. In some embodiments, the thermogelling material is a cellulosic material, such as methylcellulose, hydroxymethylcellulose or hydroxypropylmethylcellulose (HPMC). In some embodiments, the capsule comprises a shell that does not contain any film forming polymer. In some embodiments, the capsule comprises a shell and the shell comprises hydroxypropylmethylcellulose and does not comprise any film forming polymer (e.g. see [37]). In some embodiments, the formulation is an intrinsically enteric capsule (for example, Vcaps® from Capsugel).

[0115] In some embodiments, the formulation is a soft capsule. Soft capsules are capsules which may, owing to additions of softeners, such as, for example, glycerol, sorbitol, maltitol and polyethylene glycols, present in the capsule shell, have a certain elasticity and softness. Soft capsules can be produced, for example, on the basis of gelatine or starch. Gelatine-based soft capsules are commercially available from various suppliers. Depending on the method of administration, such as, for example, orally or rectally, soft capsules can have various shapes, they can be, for example, round, oval, oblong or torpedo-shaped. Soft capsules can be produced by conventional processes, such as, for example, by the Scherer process, the Accogel process or the droplet or blowing process.

##### 55 ***Culturing methods***

[0116] The bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed in, for example, references [38-40].

[0117] The solid or liquid medium used for culture may be YCFA agar or YCFA medium. YCFA medium may include (per 100ml, approximate values): Casitone (1.0 g), yeast extract (0.25 g),  $\text{NaHCO}_3$  (0.4 g), cysteine (0.1 g),  $\text{K}_2\text{HPo}_4$  (0.045 g),  $\text{KH}_2\text{PO}_4$  (0.045 g),  $\text{NaCl}$  (0.09 g),  $(\text{NH}_4)_2\text{SO}_4$  (0.09 g),  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  (0.009 g),  $\text{CaCl}_2$  (0.009 g), resazurin (0.1 mg), hemin (1 mg), biotin (1  $\mu\text{g}$ ), cobalamin (1  $\mu\text{g}$ ), *p*-aminobenzoic acid (3  $\mu\text{g}$ ), folic acid (5  $\mu\text{g}$ ), and pyridoxamine (15  $\mu\text{g}$ ).

#### ***Bacterial strains for use in vaccine compositions***

[0118] The inventors have identified that the bacterial strains of the invention are useful for treating or preventing diseases or disorders associated with a level of microbiota diversity that is reduced relative to the microbiota diversity of a healthy subject (or relative to the microbiota diversity of a population of healthy subjects) and/or diseases or disorders that are associated with reduced stability of the microbiota compared to a healthy subject (or compared to a population of healthy subjects). This is likely to be a result of the effect that the bacterial strains of the invention have on the host immune system. Therefore, the compositions of the invention may also be useful for preventing such diseases or disorders when administered as vaccine compositions. In certain such embodiments, the bacterial strains of the invention are viable. In certain such embodiments, the bacterial strains of the invention are capable of partially or totally colonising the intestine. In certain such embodiments, the bacterial strains of the invention are viable and capable of partially or totally colonising the intestine. In other certain such embodiments, the bacterial strains of the invention may be killed, inactivated or attenuated. In certain such embodiments, the compositions may comprise a vaccine adjuvant. In certain embodiments, the compositions are for administration via injection, such as via subcutaneous injection.

#### ***General***

[0119] The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., references [41] and [42-48], etc.

[0120] The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g. X + Y.

[0121] The term "about" in relation to a numerical value x is optional and means, for example,  $x \pm 10\%$ .

[0122] The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.

[0123] References to a percentage sequence identity between two nucleotide sequences means that, when aligned, that percentage of nucleotides are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of ref. [49]. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm is disclosed in ref. [50].

[0124] Unless specifically stated, a process or method comprising numerous steps may comprise additional steps at the beginning or end of the method, or may comprise additional intervening steps. Also, steps may be combined, omitted or performed in an alternative order, if appropriate.

[0125] Various embodiments of the invention are described herein. It will be appreciated that the features specified in each embodiment may be combined with other specified features, to provide further embodiments. In particular, embodiments highlighted herein as being suitable, typical or preferred may be combined with each other (except when they are mutually exclusive).

#### **MODES FOR CARRYING OUT THE INVENTION**

##### ***Example 1 - Changes in patient microbiota after *Blautia hydrogenotrophica* treatment***

###### **Summary**

[0126] The effect of *Blautia hydrogenotrophica* on the diversity and stability of patient microbiota was tested in healthy and IBS patients.

MethodologyStudy Design

5 [0127] A Phase I clinical trial was conducted in which *Blautia hydrogenotrophica* ("Blautix", strain deposited under accession number DSM 10507 and also under accession number DSM 14294) was administered to human patients having IBS or healthy human patients. Patients were administered Blautix during a dosing period (days 1-16) with the washout period being day 19-23. Faecal samples were collected from IBS & healthy subjects, placebo or Blautix treated, at: baseline, day 1 (D1) prior to treatment; end of treatment day 16 (D-16); and at end of study (EOS), which was 2-4 weeks (wash-out) posttreatment.

10

16S Amplicon sequencing

15 [0128] A Qiagen DNeasy Blood & Tissue Kit was used following the manufacturer's instructions, to extract microbial DNA from 0.2g of frozen faecal samples from IBS & Healthy subjects, placebo or Blautix treated, at: baseline, day 1 (D1) prior to treatment; end of treatment day 16 (D-16); and at end of study (EOS), which was 2-4 weeks (wash-out) post -treatment.

20 [0129] Preparation and sequencing of the 16S rRNA gene amplicons was carried out using the 16S Sequencing Library Preparation Nextera protocol developed by Illumina (San Diego, California, USA). 50 ng of each of the DNA faecal extracts was amplified using PCR and primers targeting the V3/V4 variable region of the 16S rRNA gene. The products were purified and forward and reverse barcodes were attached by a second round of adapter PCR. The resulting PCR products were purified, quantified and equimolar amounts of each amplicon were then pooled before being sent for sequencing to the commercial Supplier GATC GmbH., on either the MiSeq (2x250 bp chemistry) or HiSeq (2 x 300 bp chemistry) platforms.

25

Data Analysis (Post-sequencing)

30 [0130] The raw sequence data was merge trimmed using flash methodology. This filters out low quality reads. The USEARCH pipeline methodology (version 8.1.1861\_i86\_linux64) was used to identify singletons and hide them from the OTU (Operational Taxonomic Unit) generating step. The UPARSE algorithm was used to cluster the sequences into OTUs. Chimeric sequences generated in the amplification step were removed using the UCHIME chimera removal algorithm with the Chimeraslayer reference database (downloaded: 9th September 2016). The USEARCH global alignment algorithm was then used to map all reads, including singletons onto the remaining OTU sequences. In-house scripts were used to then group the sequences into OTUs as classified by the USEARCH global alignment algorithm. 35 Individual sequences were grouped into OTUs to give microbiome compositional information (abundance and diversity).

High-level Data analysis

40 [0131] The Bray-Curtis dissimilarity matrix was generated for each sample pairing using the Vegan library in R 3.3.1. Dataset was visualised using Principal Coordinate analysis with the Bray-Curtis dissimilarity matrix.

[0132] An in-house heatmap R function was used to generate a heatmap visualisation with hierarchical clustering based on the Bray-Curtis dissimilarity and ward linkage.

[0133] Shannon and Simpson diversity indexes were generated using the phyloseq library in R.

45 [0134] DESeq2 methodology was used to identify taxonomic variables that were significant for chosen comparisons. [0135] Permutational MANOVA was performed on the dissimilarity matrix using the Adonis function in R.

Results

50 [0136] Samples from all time points were pooled for both groups (71 IBS patients and 67 healthy controls including both the Blautix treated and placebo groups). Analysis was performed using a distance measure generated on the full microbiome dataset. Figure 1 reports that the microbiota of IBS subjects is significantly different from that of healthy subjects.

55 [0137] Diversity analysis was carried out using Observed number of predicted Taxa (OTUs), Shannon diversity index and Simpson Diversity index. Both treatment groups showed an increase in diversity at Day 16 timepoint which was significant for the observed OTUs and showed a trend for the Simpson (Raw P-value: < 0.1) (Figure 2). This increase in diversity was not observed with patients treated with the placebo. A significant decrease in microbiota diversity was observed in the untreated IBS placebo group between End of study and Day 1.

[0138] Figure 3 reports that Blautix treatment increased the microbiota network connectivity of certain health-associated

taxa. In healthy patients a substantial increase in inter-microbe connections was observed from Day 1 to Day 16 (after Blautix treatment), which suggests an increase in cooperation and microbiota structure (Figure 3A). Connectivity is correlated with diversity and stability. After the wash period the network structure reverted to a network similar to that observed on Day 1. Blautix treatment was, therefore, able to increase interconnectivity in healthy patients but the effect was lost post wash out. In IBS patients the network remained similar in terms of connectivity between Day 1 and Day 16, but an increase in connectivity was observed by the end of the study suggesting an increased microbiota structure post washout period in Blautix-treated IBS patients (Figure 3B). The effect of Blautix on microbiome connectivity was, therefore, delayed in IBS patients compared to healthy patients.

[0139] Instability/change in the microbiota profiles were represented by Bray Curtis distances between timepoints of the same subject. Bray-Curtis shows dissimilarity between species abundance profiles limited between 0-1 (0 = same; 1 = do not share any species). Treatment of IBS patients with Blautix reduced the magnitude of microbiota changes during the treatment (Fig. 4A) and after the treatment (Figures 4B-4C). This shows that Blautix increased the stability of the microbiota in IBS patients and that the change continues after the intervention. This increased stability was not observed when IBS patients were administered the placebo (Figures 4 A-C).

[0140] Figure 5 reports that there was a significant increase in microbiota diversity at the genus level for IBS patients treated with Blautix at Day 16 compared to Day 1. The diversity analysis was carried out using the Shannon diversity index applied to the Genus level (Raw p-value:0.04, Day 1 versus Day 16).

[0141] Figure 6A and Figure 6B show the changes in the mutual exclusion networks in healthy and IBS patients after Blautix treatment. In healthy individuals the mutual exclusion network becomes more dense and interconnected at Day 16, which is suggestive of increased competition and inhibition. This effect was lost, however, by the end of the study as the network structure reverted back to the initial time point during the washout period (Figure 6A). In IBS patients the effect of Blautix on mutual exclusion connectivity was to increase the network diameter over the treatment period and the washout period. This was opposite to the effect seen in the healthy individuals where the network became denser. During the washout phase for the IBS patients, multiple independent interactions were observed that were not seen previously. Multiple independent interactions represent pairs of taxa that are interacting in a manner that is independent of the rest of the network, i.e. they do not have any interactions to the rest of the network.

[0142] Visualisation of microbiota shows that after Blautix treatment there was an increased network connectivity for certain health-associated taxa (Figure 7). The health associated taxa include Clostridium cluster IV, Bifidobacterium and Prevotella. Oscillibacter is also potentially a health associated genera. These health-associated taxa are implicated in the response to treatment.

#### ***Example 2 - Protective effect in models of neurodevelopmental disorders***

##### **The BTBR mouse model**

[0143] The BTBR mouse model uses inbred, genetically modified mice that display a robust autistic-like phenotype. Deficits in social behaviours, increased repetitive behaviours and increased anxiety-related behaviours have been reported in this strain [51]. Due to this robust behavioural phenotype, the BTBR mouse is an ideal animal model to assess the efficacy of novel therapeutic agents for the treatment of autistic-related behaviours. Alleviation of such symptoms by a live biotherapeutic can also be indicative of efficacy of the biotherapeutic in the treatment of other psychiatric or neurological diseases.

##### **Mice**

[0144] Male BTBR mice were bred in house. The animals were housed in a temperature- and humidity-controlled room on a 12hr dark cycle (lights on from 7:00-19:00 hr). All experiments were conducted in accordance with the European Directive 2010/63/EEC, the requirements of S.I. No 543 of 2012, and approved by the Animal Experimentation Ethics Committee of University College Cork.

##### **Strain**

[0145] *Blautia hydrogenotrophica* bacterium deposited under accession number DSM 10507 and also under accession number DSM 14294.

[0146] Biotherapeutic was provided in glycerol stock. Live biotherapeutics were grown in the facility in anaerobic conditions.

Live biotherapeutic administration

[0147] Dosing with *Blautia hydrogenotrophica* commenced when the mice were 8 weeks old. These mice were treated once daily for 3 weeks via oral gavage.

5

Administration schedule

[0148] The vehicle for oral administration is PBS. Daily oral administration occurs via oral gavage.

10

Fecal collection

[0149] Fresh fecal samples were collected from individual mice before and after administration of *Blautia hydrogenotrophica*. At least 20 mg of fresh faeces were placed in a microcentrifuge tube, placed immediately on ice and then stored at -80°C.

15

Results

[0150] The effect of Blautix treatment on microbiota between timepoints (D14, D32) is shown in Figure 8. Significant temporal variation in the microbiota profiles was observed (p-value = 0.001) between the before treatment (D14) and after treatment (D32) study timepoints.

20

[0151] Differential analysis using DESeq2 yielded 25 significant (adjusted p-value < 0.05) differentially abundant taxa for the Blautix treatment between the D14 and D32 Autism study timepoints. The taxa are listed in **Table 1** below.

25

**Table 1.** Significant differentially abundant taxa between D14 and D32 time points in the autism study. A positive fold change is interpreted as increased at D32 when compared to D14.

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value	
2440650	Genus	Clostridium XIVa	19.706	3.008	6.9E-10	
307526	Species	Bacteroides acidifaciens	11.275	0.912	5.0E-33	
39008	Species	Bacteroides acidifaciens	10.501	1.345	1.0E-13	
277773	Species	Alistipes finegoldii	9.954	0.906	2.8E-26	
1105465	Genus	Barnesiella	9.255	0.923	2.8E-22	
943687	Family	Porphyromonadaceae	9.200	0.850	1.1E-25	
47662	Species	Barnesiella intestinihominis	8.844	0.988	7.0E-18	
181003	Genus	Alistipes	8.370	2.069	4.2E-04	
1282905	Species	Barnesiella intestinihominis	7.373	1.004	2.8E-12	
1370810	Species	Barnesiella intestinihominis	6.633	1.986	0.006	
40	1203483	Species	Bacteroides acidifaciens	6.599	1.584	2.7E-04
74179	Species	Alistipes massiliensis	6.318	1.899	0.006	
1640334	Species	Barnesiella intestinihominis	6.258	2.066	0.013	
76239	Family	Lachnospiraceae	6.202	1.229	4.6E-06	
45	308030	Species	Barnesiella intestinihominis	6.196	1.451	1.8E-04
1156020	Family	Erysipelotrichaceae	5.827	1.607	0.002	
712755	Species	Barnesiella intestinihominis	5.614	1.749	0.008	
11297	Family	Porphyromonadaceae	5.450	1.021	1.0E-06	
50	2218722	Genus	Clostridium IV	3.983	1.017	0.001
			Clostridium			
594012	Species	lactatifermentans	2.900	0.952	0.013	
453043	Species	Eubacterium ventriosum	-3.675	1.260	0.018	
451019	Species	Barnesiella intestinihominis	-4.055	1.540	0.041	
466087	Species	Akkermansia muciniphila	-6.727	0.876	2.5E-13	
55	2153421	Genus	Blautia XIVa	-8.051	2.577	0.010
866478	Species	Barnesiella intestinihominis	-8.961	0.846	9.3E-25	

Summary

[0152] In a mouse model of autism in which animals were administered Blautix, a significant variation on their microbiome was observed, including a substantial net increase in bacterial diversity.

5

**Example 3 -Effect in models of cerebral ischemia**Summary

[0153] The protective effect of *Blautia hydrogenotrophica* was tested in mouse models of cerebral ischemia. To this end three groups of 5-17 mice were tested. Only normally behaving animals were included in the study. The first dosing day was Day -14. One group received freeze dried bacteria daily from the first dosing day until termination. The control groups received either vehicle or lyobuffer.

[0154] On Day 1, all mice were anesthetized. A midline incision was created in the ventral side of the neck to expose the right and left common carotid-arteries. A cerebral ischemia-reperfusion I/R model was then induced by bilateral common carotid artery occlusion (BCCAO) using vascular clips for 15 minutes. At the end of each occlusion, the clips were removed.

Strain

[0155] *Blautia hydrogenotrophica* bacterium deposited under accession number DSM 10507 and also under accession number DSM 14294.

Administration Schedule

[0156]

No. of Animals	Treatment	Dose Level (mg/kg)	Dose Volumes (ml/kg or ml/animal)
12	PBS (negative control)	n/a	10
17	Freeze-dried Powder	7.8 mg in 100 $\mu$ l	100 $\mu$ l per animal
13	Freeze-dried Bacteria	15.6 mg in 100 $\mu$ l (bacteria dose = 2 $\times$ 10 <sup>8</sup> )	100 $\mu$ l per animal

Study design

[0157] Days -14 to 14: Daily dose of PBS control (lyobuffer), freeze dried powder control (vehicle) or freeze dried bacteria (Blautix).

[0158] Day 1: Cerebral ischemia-reperfusion I/R model induced by surgery.

[0159] Day 14: Half of the mice in each group were terminated.

[0160] Day 14 to 28: Daily dose of PBS control (lyobuffer), freeze dried powder control (vehicle) or freeze dried bacteria (Blautix) for the remaining mice in each group.

[0161] Day 28: Termination of remaining mice.

[0162] Faecal pellets were collected at three time points: Day -14, Day 14 and Day 28. Each take was carried out in a sterile environment (fully aseptic = cleaned between animals), with every mouse being taken out of the cage and placed separately into a new sterile box for individual pellet harvesting. As many pellets as possible were collected in order to reach a minimum of 80mg and preferably 100mg of material per mouse.

Results

[0163] No significant differences in microbiota profiles between the Blautix treatment, Vehicle and Lyobuffer groups were detected at D-14 (p-value= 0.177) before administration of Blautix (see Figure 9A). However, significant differences were observed in microbiota profiles between the different treatment groups at Day 14 (see Figure 9B) with a p-value of 0.011 observed. The inventors further assessed the temporal variation in the microbiota of the Blautix treated group

and found a significant difference (see Figure 9C) with a p-value of 0.002 observed.

[0164] Differential analysis using DESeq2 yielded significant (adjusted p-value <0.05) differentially abundant taxa for the Vehicle, Lyobuffer and Blautix treatment between timepoints in the Stroke study, as shown in Table 2, demonstrating a longer term impact on bacterial diversity imparted by Blautix. The taxa for the Blautix treatment are listed in Table 3, Table 4 and Table 5.

**Table 2.** Significant differentially abundant taxa between time points in the Stroke study.

	D-14->D14	D14->D28	D-14->D28
Vehicle	4	0	2
Lyobuffer	17	2	0
Blautix	7	14	12

**Table 3.** Significant differentially abundant taxa between D-14 and D14 timepoints for the Blautix treatment in the Stroke study. A positive fold change is interpreted as increased at D14 when compared to D-14.

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
321825	Family	Ruminococcaceae	1.647	0.470	0.027
74771	Species	Alistipes massiliensis	1.530	0.442	0.027
567799	Genus	Alistipes	-1.215	0.308	0.008
77091	Genus	Clostridium	-1.634	0.489	0.036
472737	Family	Lachnospiraceae	-2.585	0.667	0.008
615246	Family	Lachnospiraceae	-3.003	0.711	0.007
166882	Family	Lachnospiraceae	-5.547	1.406	0.008

**Table 4.** Significant differentially abundant taxa between D14 and D28 timepoints for the Blautix treatment in the Stroke study. A positive fold change is interpreted as increased at D28 when compared to D14.

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
1101936	Order	Clostridiales	3.275	0.709	0.001
218505	Species	Roseburia faecis	2.568	0.630	0.002
948888	Genus	Bamesiella	2.499	0.575	0.001
612631	Genus	Clostridium XIVa	2.473	0.723	0.011
201398	Phylum	Bacteroidetes	2.045	0.605	0.011
1370810	Species	Bamesiella intestinihominis	1.878	0.579	0.016
770554	Species	Alistipes putredinis	1.868	0.626	0.033
558330	Genus	Prevotella	1.795	0.453	0.002
943687	Family	Porphyromonadaceae	1.586	0.546	0.039
308030	Species	Bamesiella intestinihominis	1.324	0.361	0.005
176124	Phylum	Bacteroidetes	1.163	0.294	0.002
565518	Species	Oscillospira guilliermondii	-1.571	0.488	0.016
544582	Species	Flavonifractor plautii	-1.599	0.569	0.050
25678	Species	Mucispirillum schaedleri	-2.751	0.640	0.001

**Table 5.** Significant differentially abundant taxa between D-14 and D28 timepoints for the Blautix treatment in the Stroke study. A positive fold change is interpreted as increased at D28 when compared to D-14.

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
688867	Genus	Clostridium XIVa	8.296	1.136	3.8E-11
612631	Genus	Clostridium XIVa	7.814	1.348	3.1E-07
560658	Family	Lachnospiraceae	5.241	1.243	0.001
929749	Species	Eubacterium ruminantium	3.190	0.829	0.003
518034	Species	Desulfovibrio fairfieldensis	3.098	0.982	0.024
74771	Species	Alistipes massiliensis	2.548	0.714	0.007
23310	Species	Odoribacter laneus	1.621	0.475	0.011
117624	Order	Clostridiales	-1.748	0.612	0.049
411272	Genus	Clostridium XIVa	-2.923	1.019	0.049
39008	Species	Bacteroides acidifaciens	-2.953	0.816	0.007
331352	Genus	Clostridium XIVa	-3.969	0.626	1.6E-08
77091	Genus	Clostridium	-4.247	1.426	0.039

**[0165]** Differential analysis using DESeq2 yielded significant (adjusted p-value <0.05) differentially abundant taxa for the Blautix treatment vs. Vehicle as well as Blautix treatment vs. Lyobuffer for the Stroke study timepoints, as shown in Table 6. The taxa are listed in Table 7, Table 8 and Table 9.

**Table 6.** Significant differentially abundant taxa for the Blautix treatment in the Stroke study.

	D-14	D14	D28
Blautix vs. Vehicle	0	10	0
Blautix vs. Lyobuffer	2	13	0

**Table 7.** Significant differentially abundant taxa for the Blautix treatment vs. Vehicle at D14 in the Stroke study.

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
25678	Species	Mucispirillum schaedleri	2.604	0.688	0.014
3119687	7 Family	Lachnospiraceae	2.445	0.642	0.014
321825	Family	Ruminococcaceae	2.174	0.564	0.014
627	Genus	Clostridium XIVa	1.915	0.601	0.043
308030	Species	Barnesiella intestinihominis	-1.324	0.419	0.043
137081C	Species	Barnesiella intestinihominis	-1.540	0.425	0.019
187271	Species	Ruminococcus flavefaciens	-3.475	1.065	0.042
277773	Species	Alistipes finegoldii	-3.751	1.178	0.043
940566	Species	Staphylococcus lentus	-5.228	1.519	0.026
930972	Genus	Staphylococcus	-5.418	1.536	0.023

**Table 8.** Significant differentially abundant taxa for the Blautix treatment vs. Lyobuffer at D-14 in the Stroke study

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
1161472	Family	Lachnospiraceae	6.511	1.403	0.001

(continued)

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
392940	Kingdom	Bacteria	-5.169	1.346	0.022

5

**Table 9.** Significant differentially abundant taxa for the Blautix treatment vs. Lyobuffer at D14 in the Stroke study

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
25678	Species	Mucispirillum schaedleri	2.704	0.753	0.012
1379349	Genus	Clostridium XIVa	2.517	0.771	0.027
742656	Species	Oscillibacter valericigenes	1.738	0.459	0.009
558330	Genus	Prevotella	-1.634	0.406	0.006
		Barnesiella			
1370810	Species	intestinihominis	-1.780	0.390	0.001
		Barnesiella			
712755	Species	intestinihominis	-1.827	0.464	0.006
		Barnesiella			
47662	Species	intestinihominis	-2.109	0.606	0.014
		Barnesiella			
1640334	Species	intestinihominis	-2.260	0.693	0.027
1105465	Genus	Barnesiella	-2.306	0.627	0.010
161658	Family	Lachnospiraceae	-2.565	0.816	0.037
277773	Species	Alistipes finegoldii	-3.619	1.034	0.014
		Ruminococcus			
187271	Species	flavefaciens	-3.924	1.057	0.010
459041	Species	Lactobacillus johnsonii	-4.029	0.981	0.006

30

Summary

**[0166]** Blautix effects a significant increase in microbiota diversity throughout the period of the study in a mouse model of stroke, when compared to lyobuffer or vehicle control.

35

**Example 4 - Protective effect in models of neuroinflammatory conditions**

**[0167]** Experimental Autoimmune Encephalomyelitis (EAE) is a mouse model of CNS inflammation that mirrors many aspects of the human disease MS and EAE is the most commonly used experimental model for human MS. EAE is also used more generally as a model for CNS-specific autoimmune disorders [52] and for other specific conditions, including acute disseminated encephalomyelitis. EAE is induced using immunisation with myelin peptides and adjuvants to elicit an immune and inflammatory response that closely corresponds to the mechanisms underlying many autoimmune and inflammatory disorders of the CNS, and in particular MS. Many therapies showing efficacy in EAE have also shown efficacy in treatment of MS in human patients [52]. Most importantly, EAE reproduces key features of MS, including inflammation, demyelination, axonal loss and gliosis. The effects of demyelination are mainly restricted to the spinal cord in EAE, with little alteration of the brain stem and the cerebellum. In EAE the CD4+ T cells are the dominant cell population found in the CNS.

50

Methodology

**[0168]** *Blautia hydrogenotrophica* ("Blautix", strain deposited under accession number DSM 10507 and also under accession number DSM 14294) was used as a freeze-dried powder and reconstituted as required. 12 adult female C57BL/6J mice were used.

**[0169]** On Day 0 and Day 7, animals were administered with an emulsion containing MOG35-55 and complete Freund's adjuvant (CFA) supplemented with Mycobacterium Tuberculosis H37Ra by subcutaneous injections under gas (isoflurane) anaesthesia. On Day 0, two subcutaneous injections were performed in the flanks; one in each of the lower quadrant of the back. On Day 7, two subcutaneous injections were performed in the flanks, one in each of the upper quadrant of the back.

[0170] On Day 0 and Day 2, animals were administered with pertussis toxin (PTx) in phosphate buffered saline (PBS) by intra-peritoneal injections. On Day 0, PTx administration was performed after MOG injections.

[0171] Treatments with Blautix or controls were administered from Day -14 according to the following schedule:

5 Day 0: MOG/CFA, once, SC  
 Day 0: PTx, once, IP  
 Day 2, PTx, once, IP  
 Day 7: MOG/CFA, once, SC

10 [0172] Treatments were administered within 15 minutes of their preparation. Blautix was administered at a dose of 2 x 10<sup>8</sup>; 100µl/mouse.

[0173] From Day 0 until the end of the experiment, animals were scored daily for clinical signs of EAE, including paresis and paralysis of the tail and/or limbs.

15 [0174] On Day -14, Day -1 and Day 34, faecal pellets were collected from each animal, immediately snap-frozen and stored at -80°C.

### Results

20 [0175] The effect of Blautix treatment on microbiota between timepoints (D-14, D-1, D34) for the MS model is shown in Figure 10. Significant temporal variation in the microbiota profiles was observed (p-value = 0.001) for the study timepoints.

25 [0176] Differential analysis using DESeq2 yielded significant (adjusted p-value < 0.05) differentially abundant taxa for the Blautix treatment between study timepoints, as shown in Table 10. The taxa are listed in Table 11, Table 12 and Table 13.

**Table 10.** Significant differentially abundant taxa between timepoints in the MS study.

	D-14->D-1	D-1->D34	D-14->D34
MS (Blautix)	42	30	58

**Table 11.** Significant differentially abundant taxa between D-14 and D-1 timepoints in the MS study. A positive fold change is interpreted as increased at D-1 when compared to D-14.

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
1105465	Genus	Barnesiella	8.076	0.702	2.2E-28
48633	Genus	Clostridium XIVa	7.304	0.825	7.0E-17
490405	Species	Turicibacter sanguinis	6.824	0.778	1.0E-16
491106	Species	Flavonifractor plautii	5.116	0.923	4.3E-07
43241	Genus	Clostridium XIVa	5.041	0.739	2.2E-10
948888	Genus	Barnesiella	4.649	0.605	4.3E-13
47662	Species	Barnesiella intestinihominis	4.276	0.501	5.1E-16
1288839	Family	Lachnospiraceae	4.117	1.170	0.003
11297	Family	Porphyromonadaceae	4.081	0.600	2.2E-10
198591	Family	Lachnospiraceae	3.757	0.788	2.3E-05
49543	Family	Lachnospiraceae	3.275	0.897	0.002
1009304	Species	Oscillospira guilliermondii	3.140	1.043	0.015
930464	Species	Insolitospillum peregrinum	2.804	1.033	0.029
1793164	Genus	Parasutterella	2.720	0.576	2.6E-05
1260915	Kingdom	Bacteria	2.678	0.804	0.006
36112	Species	Clostridium leptum	2.584	0.887	0.018
181003	Genus	Alistipes	2.581	0.555	3.3E-05
149837	Family	Lachnospiraceae	2.434	0.678	0.002
1056232	Genus	Clostridium XIVa	2.308	0.856	0.030

(continued)

	OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
5	770554	Species	<i>Alistipes putredinis</i>	2.223	0.556	0.001
	1176501	Family	<i>Lachnospiraceae</i>	2.079	0.758	0.028
	33530	Species	<i>Acetatifactor muris</i>	1.965	0.569	0.004
	43033	Genus	<i>Alistipes</i>	1.788	0.379	2.6E-05
	576748	Family	<i>Ruminococcaceae</i>	1.740	0.603	0.019
	50759	Species	<i>Oscillospira guilliermondii</i>	1.570	0.409	0.001
10			<i>Pseudoflavonifractor</i>			
	592877	Species	<i>capillosus</i>	1.512	0.418	0.002
	712755	Species	<i>Barnesiella intestinihominis</i>	1.509	0.502	0.015
	375558	Species	<i>Barnesiella intestinihominis</i>	1.505	0.554	0.029
	307526	Species	<i>Bacteroides acidifaciens</i>	1.499	0.492	0.014
	74641	Species	<i>Bacteroides acidifaciens</i>	1.418	0.532	0.032
15	943687	Family	<i>Porphyromonadaceae</i>	1.162	0.397	0.018
	791734	Genus	<i>Clostridium XIVa</i>	-1.064	0.377	0.023
	19031	Species	<i>Anaerotruncus colihominis</i>	-1.391	0.516	0.030
	74179	Species	<i>Alistipes massiliensis</i>	-1.810	0.305	4.7E-08
			<i>Anaeroplasma</i>			
	211238	Species	<i>abactoclasticum</i>	-2.662	0.859	0.012
20	76239	Family	<i>Lachnospiraceae</i>	-2.721	0.668	4.2E-04
	743544	Genus	<i>Clostridium XIVa</i>	-3.014	0.672	7.0E-05
	993522	Genus	<i>Clostridium XIVa</i>	-3.394	0.708	2.2E-05
	76325	Genus	<i>Lactobacillus</i>	-3.621	0.575	5.2E-09
	209309	Family	<i>Lachnospiraceae</i>	-3.857	1.295	0.016
	567799	Genus	<i>Alistipes</i>	-5.435	0.634	4.3E-16
25	77091	Genus	<i>Clostridium</i>	-6.877	1.048	1.0E-09

**Table 12.** Significant differentially abundant taxa between D-1 and D34 timepoints in the MS study. A positive fold change is interpreted as increased at D34 when compared to D-1.

	OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
40	1370810	Species	<i>Barnesiella intestinihominis</i>	4.794	1.196	0.001
			<i>Parasutterella</i>			
	1684470	Species	<i>exrementihominis</i>	4.434	1.167	0.002
			<i>Eubacterium</i>			
	1070245	Species	<i>plexicaudatum</i>	3.870	0.961	0.001
	518034	Species	<i>Desulfovibrio fairfieldensis</i>	3.867	0.962	0.001
45	1482481	Species	<i>Clostridium disporicum</i>	3.228	1.112	0.029
	567799	Genus	<i>Alistipes</i>	3.218	0.864	0.002
	1404432	Species	<i>Bacteroides acidifaciens</i>	2.978	0.835	0.004
	1067514	Genus	<i>Barnesiella</i>	2.967	0.921	0.011
	76325	Genus	<i>Lactobacillus</i>	2.893	0.683	0.001
	307526	Species	<i>Bacteroides acidifaciens</i>	2.218	0.351	1.8E-08
50	1288839	Family	<i>Lachnospiraceae</i>	2.084	0.746	0.035
	866478	Species	<i>Barnesiella intestinihominis</i>	1.936	0.647	0.022
	23133	Family	<i>Ruminococcaceae</i>	1.840	0.544	0.007
	472737	Family	<i>Lachnospiraceae</i>	1.697	0.524	0.011
	842401	Order	<i>Clostridiales</i>	1.601	0.535	0.022

(continued)

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value	
5	39008	Species	Bacteroides acidifaciens	1.494	0.390	0.002
	74179	Species	Alistipes massiliensis	1.426	0.328	3.9E-04
	277773	Species	Alistipes finegoldii	1.323	0.461	0.029
	76234	Family	Lachnospiraceae	-1.183	0.333	0.004
10	948888	Genus	Barnesiella	-1.453	0.520	0.035
	150155	Family	Lachnospiraceae	-1.609	0.421	0.002
	783115	Family	Desulfovibrionaceae	-2.262	0.608	0.002
	773427	Species	Anaerotruncus colihominis	-2.443	0.661	0.003
15	201157	Family	Lachnospiraceae	-2.587	0.754	0.006
	596894	Genus	Clostridium XIVa	-2.616	0.909	0.029
	43033	Genus	Alistipes	-3.236	0.718	2.2E-04
	1793164	Genus	Parasutterella	-3.758	0.632	1.4E-07
20	49543	Family	Lachnospiraceae	-4.849	0.920	5.5E-06
	490405	Species	Turicibacter sanguinis	-5.152	0.704	2.5E-11
	48282	Family	Lachnospiraceae	-5.460	0.666	4.7E-14

**Table 13.** Significant differentially abundant taxa between D-14 and D34 timepoints in the MS study. A positive fold change is interpreted as increased at D34 when compared to D-14.

OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value	
30	1105465	Genus	Barnesiella	7.221	0.754	2.1E-19
	48633	Genus	Clostridium XIVa	6.734	0.959	8.7E-11
	1288839	Family	Lachnospiraceae	5.820	0.811	3.5E-11
	518034	Species	Desulfovibrio fairfieldensis	5.459	0.999	8.3E-07
35		Parasutterella				
	1684470	Species	excrementihominis	5.289	1.408	0.001
	1482481	Species	Clostridium disporicum	4.947	1.295	0.001
	1370810	Species	Barnesiella intestinihominis	4.734	1.263	0.001
40	1070245	Species	Eubacterium plexicaudatum	4.620	0.794	1.3E-07
	1067514	Genus	Barnesiella	4.544	1.103	2.8E-04
	1575843	Species	Clostridium ruminantium	4.393	1.743	0.040
	43241	Genus	Clostridium XIVa	4.284	0.817	2.4E-06
45	47662	Species	Barnesiella intestinihominis	4.273	0.478	3.8E-17
		Lachnospiraceae incertae				
	1728285	Genus	sedis	4.204	1.221	0.003
	11297	Family	Porphyromonadaceae	3.921	0.577	3.4E-10
50	307526	Species	Bacteroides acidifaciens	3.539	0.534	9.9E-10
	198591	Family	Lachnospiraceae	3.273	0.762	1.4E-04
	236126	Species	Oscillospira guilliermondii	3.175	1.086	0.015
	930464	Species	Insolitispillum peregrinum	3.152	0.848	0.001
55	948888	Genus	Barnesiella	3.040	0.629	1.6E-05
	491106	Species	Flavonifractor plautii	3.039	1.170	0.034
	563211	Family	Lachnospiraceae	2.564	0.965	0.030
	149837	Family	Lachnospiraceae	2.562	0.890	0.016
55	770554	Species	Alistipes putredinis	2.520	0.455	6.2E-07
	1260915	Kingdom	Bacteria	2.505	0.677	0.001
	36112	Species	Clostridium leptum	2.483	0.916	0.026

(continued)

	OTU_ID	Lowest Level	Classification	log2 fold change	st error	adjusted p-value
5	1056232	Genus	Clostridium XIVa	2.319	0.664	0.002
	39008	Species	Bacteroides acidifaciens	2.107	0.274	9.9E-13
	23133	Family	Ruminococcaceae	2.049	0.614	0.004
	74641	Species	Bacteroides acidifaciens	2.002	0.457	1.0E-04
10	712755	Species	Barnesiella intestinihominis	1.977	0.470	2.0E-04
	277773	Species	Alistipes finegoldii	1.881	0.388	1.6E-05
	1404432	Species	Bacteroides acidifaciens	1.805	0.563	0.006
	1176501	Family	Lachnospiraceae	1.654	0.630	0.032
15	544582	Species	Flavonifractor plautii	1.418	0.540	0.032
	76234	Family	Lachnospiraceae	-0.991	0.389	0.038
	80190	Family	Lachnospiraceae	-1.113	0.348	0.006
	182471	Order	Clostridiales	-1.315	0.472	0.021
	494032	Species	Clostridium oroticum	-1.502	0.580	0.034
20	2367602	Order	Clostridiales	-1.518	0.472	0.006
	74771	Species	Alistipes massiliensis	-1.617	0.408	0.001
	172154	Genus	Clostridium XIVa	-1.628	0.442	0.001
	993522	Genus	Clostridium XIVa	-1.799	0.594	0.011
	791734	Genus	Clostridium XIVa	-1.842	0.387	2.2E-05
25	150155	Family	Lachnospiraceae	-1.859	0.532	0.002
	743544	Genus	Clostridium XIVa	-2.196	0.558	0.001
	567799	Genus	Alistipes	-2.378	0.513	3.9E-05
	96345	Genus	Clostridium XIVa	-2.528	0.667	0.001
30	19031	Species	Anaerotruncus colihominis	-2.575	0.610	1.9E-04
	201157	Family	Lachnospiraceae	-2.615	0.866	0.011
	578360	Family	Lachnospiraceae	-2.870	0.586	1.4E-05
	76239	Family	Lachnospiraceae	-3.325	0.631	2.3E-06
	1165458	Family	Lachnospiraceae	-3.346	0.754	8.1E-05
35	773427	Species	Anaerotruncus colihominis	-3.475	0.776	7.0E-05
	209309	Family	Lachnospiraceae	-3.639	1.042	0.002
	320120	Genus	Clostridium XIVa	-3.670	0.811	5.9E-05
	1628488	Species	Vallitalea guaymasensis	-4.144	1.538	0.027
40	48282	Family	Lachnospiraceae	-4.653	1.012	4.5E-05
	77091	Genus	Clostridium	-7.493	1.192	7.9E-09

### Summary

45 [0177] Blautix effects a significant increase in microbiota diversity and results in significant temporal variation during treatment in an animal model for multiple sclerosis.

### **Sequences**

50 [0178]

SEQ ID NO:1 (*Blautia stercoris* strain GAM6-1 16S ribosomal RNA gene, partial sequence - HM626177)

55 1 tgcaagtgcg gcaaggcgct tacgacagaa cttcgaaaaa aagatgttaag ggactgagcg  
 61 gcggacgggt gagtaacgcg tggtaacct gcctcataca gggggataac agttggaaac  
 121 ggctgctaat accgcataag cgcacggat cgcatac agtgtgaaaaa actccggatgg

181 tatgagatgg acccgcgtct gattagctag ttggaggggt aacggcccac caaggcgacg  
241 atcagtagcc ggcctgagag ggtgaacggc cacattggga ctgagacacg gcccagactc  
301 ctacgggagg cagcagtggg gaatattgca caatggggga aaccctgatg cagcgcacgccc  
361 gcgtgaagga agaagtatct cggtatgtaa acttctatca gcagggaaaga aaatgacggt  
421 acctgactaa gaagccccgg ctaactacgt gccagcagcc gcggtaatac gtagggggca  
481 agcgttatcc ggatttactg ggtgtaaagg gagcgtagac ggaagagcaa gtctgtatgt  
541 aaaggctggg gcttaacccc aggactgcat tggaaactgt ttttcttgag tgccggagag  
601 gtaagcggaa ttccttagtgt agcggtgaaa tgcgttagata tttaggaggaa caccagtggc  
661 gaaggcggct tactggacgg taactgacgt tgaggctcga aagcgtgggg agcaaacagg  
721 attagataacc ctggtagtcc acgcccgtaaa cgatgaatac tagtgtttgg ggagcaaagc  
781 tttcgggtgc cgcagcaaac gcaataagta ttccacctgg ggagtacgtt cgcaagaatg  
841 aaactcaaag gaattgacgg ggacccgcac aagcggtgga gcatgtggtt taattcgaag  
901 caacgcgaag aaccttacca agtcttgaca tcgatctgac cggtcgtaa tggaaccttt  
961 cttcgggac agagaagaca ggtggtgcat ggttgcgtc agctcgtgtc gtgagatgtt  
1021 gggtaagtc ccgcaacgag cgcaacccct atcctcagta gccagcaggt gaagctggc  
1081 actctgtggaa gactgccagg gataacctgg aggaaggcgg ggacgcacgtc aaatcatcat  
1141 gccccttatg atttgggcta cacacgtgct acaatggcgt aaacaaaggg aagcgagccc  
1201 gcgagggggaa gcaaatccca aaaataacgt cccagttcgg actgcagttc gcaactcgac  
1261 tgcacgaagc tggaatcgct agtaatcgcg aatcagaatg tgcgtgtgaa tacgttccccg  
1321 ggtcttgtac acaccgccccg tcacaccatg ggagtctgta acgccccgaag tc

SEQ ID NO:2 (*Blautia wexlerae* strain WAL 14507 16S ribosomal RNA gene, partial sequence - EF036467)

1201 agatggagca aatcccaaaa ataacgtccc agttcggact gtagtctgca acccgactac  
1261 acgaagctgg aatcgctagt aatcgccgat cagaatgccg cggtgaatac gttcccggt  
1321 cttgtacaca ccgcccgtca caccatggg gtcagtaacg cccgaagtca gtgaccta  
1381 tgcaaagaag gagctgccga aggccggacc gatgactggg gtgaagtcgt aacaagg  
5

SEQ ID NO:3 (consensus 16S rRNA sequence for *Blautia stercoris* strain 830)

10 TTTKGTCGGCTCAGGATGAACGCTGGCGCGTGTAAACACATGCAAGTCGAGCGAAGCGCTTACGACAGAACCTT  
CGGGGGAAAGATGTAAGGGACTGAGCGCGGACGGGTGAGTAACCGTGGTAACCTGCCTCATACAGGGGGATAACA  
GTTGGAAACGGCTGCTAATACCCATAAGCGCACAGTATCGCATGATACTAGTGTGAAAAACTCCGGTGGTATGAGAT  
15 GGACCCCGCGTCTGATTAGCTAGTTGGAGGGTAACGCCACCAAGGCGACGATCAGTAGCCGGCTGAGAGGGTGA  
ACGGCCACATTGGGACTGAGACACGCCAGACTCCTACGGGAGGCAGCAGTGGGAATATTGCACAATGGGGAAA  
CCCTGATGCAGCGACGCCCGTGAAGGAAGAAGTATCTGGTATGTAAACTTCTATCAGCAGGGAAAGAAAATGACGG  
TACCTGACTAAGAAGCCCGCTAACTACGTGCCAGCAGCCGGTAATACGTAGGGGCAAGCGTTATCCGGATT  
20 ACTGGGTGTAAAGGGAGCGTAGACGGAAGAGCAAGTCTGATGTGAAAGGCTGGGCTTAACCCAGGACTGCATTGG  
AAACTGTTTCTTGAGTGCCGGAGAGGTAAGCGGAATTCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAA  
CACCACTGGCGAAGGCAGCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGAGCAAACAGGATTAGAT  
ACCCGGTAGTCCACGCCGTAAACGATGAATACTAGGGTTGGGAGCAAAGCTTCCGGTGCAGCAAACCGAA  
25 TAAGTATTCCACCTGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGACCCGACAAGCGTGGAG  
CATGTGGTTATTGAAAGCAACCGAAGAACCTTACCAAGTCTGACATCGATCTGACCGGTTCTGAAAGTCCC  
TCCTTCGGGACAGAGAAGACAGGTGGTCATGGTTGTCGTCACTCGTGTGAGATGTTGGGTAAGTCCC  
30 CGAGCGCAACCCCTATCGTCAGTAGCCAGCAGGTAAAGCTGGGACTCTGAGGAGACTGCCAGGGATAACCTGGAGG  
AAGGCGGGACGACGTCAAATCATCATGCCCTTATGATTGGCTACACACGTGCTACAATGGCTAAACAAAGGG  
AAGCGAGCCCGCAGGGGGAGCAAATCCAAAATAACGTCGGACTGCAACTCGACTGCACGA  
AGCTGGAATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCGGTCTGTACACACC  
35 ACCATGGGAGTCAGTAACGCCGAAGTCAGTGACCCAACCTAGGGAGGGAGCTGCCAGGCAGGATTGATAACTG  
GGGTGAAGTCTAGGGGGT

SEQ ID NO:4 (consensus 16S rRNA sequence for *Blautia wexlerae* strain MRX008)

40

45

50

55

TTCATTGAGACTTCGGTGGATTAGATTCTATTCTAGTGGCGGACGGGTGAGTAACCGTGGGTAACCTGCCCTAT  
ACAGGGGGATAACAGTCAGAAATGGCTGCTAATACCGCATAAGCGCACAGAGCTGCATGGCTCAGTGTGAAAAACTC  
5 CGGTGGTATAAGATGGACCCCGCGTTGGATTAGCTTGGTGGGTAACGCCACCAAGGCGACGATCCATAGCCG  
GCCTGAGAGGGTGAACGCCACATTGGGACTGAGACACGCCAGACTCCTACGGGAGGCAGCAGTGGGAATATTG  
ACAATGGGGAAACCCCTGATGCAGCGACGCCCGTGAAGGAAGAAGTATCTGGTATGTAAACCTATCAGCAGG  
10 GAAGATAGTGACGGTACCTGACTAAGAAGCCCGCTAACTACGTGCCAGCAGCCGGTAATACGTAGGGGCAAG  
CGTTATCCGGATTTACTGGGTGAAAGGGAGCGTAGACGGTGTGGCAAGTCTGATGTGAAAGGCATGGCTAACCT  
GTGGACTGCATTGAAACTGTCATACTTGAGTGCCGGAGGGTAAGCGGAATTCTAGTGTAGCGGTGAAATCGTA  
GATATTAGGAGGAACACCAAGTGGCGAAGGCCGTTACTGGACGTAACGTGTTGAGGCTCGAAAGCGTGGGAGC  
15 AACAGGATTAGATAACCGTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTCNGGGAGCATGGCTTCGGTG  
CCGTCGCAAACGCAGTAAGTATTCCACCTGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGACCC  
GCACAAGCGGTGGAGCATGTGGTTAATTGAAACGCAACGCGAAGAACCTACCAAGTCTGACATCCGCTGACCGA  
TCCTTAACCGATCTTCCTCGGACAGGCGAGACAGGTGGTGCATGGTTGTCGTAGCTCGTGTGAGATGTT  
GGGTTAAGTCCCGCAACGAGCGAACCCCTATCCTCAGTAGCCAGCATTAAGGTGGCACTCTGGGAGACTGCCA  
20 GGGATAACCTGGAGGAAGGCCGGATGACGTCAAATCATGCCCTATGATTGGCTACACACGTGCTACAAT  
GGCGTAAACAAAGGGAAAGCGAGATCGTAGAGATGGAGCAAATCCAAAATAACGTCCCAGTCGACTGTAGTCTGC  
AACCCGACTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGAATGCCCGGTGAATACGTTCCGGGTCTTGT  
25 CACACCGCCCGTCACACCATGGGAGTCAGTAACGCCGAAGTCAGTGACCTAACTGCAAAGAAGGAGCTGCCGAA

SEQ ID NO:5 (*Blautia hydrogenotrophica* strain S5a36 16S ribosomal RNA gene, partial sequence - X95624.1)

30

35

40

45

50

55

1 gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac gaagcgatag agaacggaga  
 5 61 tttcggttga agttttctat tgactgagtg gcggacgggt gagtaacgcg tgggtaacct  
 121 gcccatacata gggggataac agttagaaat gactgctaatt accgcataag cgcacagct  
 181 181 cgcataaaggc ggtgtaaaaa actgaggtgg tataggatgg acccgcgtt gattagctag  
 241 241 ttggtgaggt aacggccac caaggcgacg atccatagcc ggcctgagag ggtgaacggc  
 301 301 cacattggga ctgagacacg gcccaaactc ctacggagg cagcagtggg gaatattgca  
 361 361 caatggggga aaccctgatg cagcgcacg gcgtgaagga agaagtatct cggtatgtaa  
 421 421 acttctatca gcagggaaaga aagtgcggt acctgactaa gaagccccgg ctaattacgt  
 481 481 gccagcagcc gcggtaatac gtaagggca agcgttatcc ggatttactg ggtgtaaagg  
 541 541 gagcgttagac ggtttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcatt  
 601 601 tggaaactgt cagacttgag tgccggagag gcaagcggaa ttcctagtgt agcggtgaaa  
 661 661 tgcgtagata ttaggaggaa caccagtggc gaaggcgcc tgctggacgg taactgacgt  
 721 721 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa  
 781 781 ccatgaaatac taggtgtcgg gtggcaaagc cattcggcgc cgcagcaaac gcaataagta  
 841 841 ttcccacctg gggagttacgt tcgcaagaat gaaactcaaa ggaattgacg gggaccgc  
 901 901 caagcgggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaaccttacc aaatcttgc  
 961 961 atccctctga ccgggaagta atgttccctt ttcttcgaa cagaggagac aggtggtgca  
 1021 1021 tgggtgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct  
 1081 1081 tattcttagt agccagcagg tagagctggg cactctaggg agactgccag ggataacctg  
 1141 1141 gaggaagggtg gggatgacgt caaatcatca tgccccttat gatttggct acacacgtgc  
 1201 1201 tacaatggcg taaacaaagg gaagcgaagg ggtgacctgg agcaaattctc aaaaataacg  
 1261 1261 tctcagttcg gattgttagtc tgcaactcga ctacatgaag ctggaatcgc tagtaatcgc  
 1321 1321 gaatcagaat gtcgcggta atacgttccc gggtcttta cacaccgccc gtcacaccat  
 1381 1381 gggagtcagt aacgcccggaa gtcagtgacc caaccnaaag gagggagctg ccgaagggtgg  
 1441 1441 gactgataac tggggta

## 35 REFERENCES

## [0179]

40 [1] Spor et al. (2011) *Nat Rev Microbiol.* 9(4):279-90.  
 [2] Tap et al. (2009), *Environ Microbiol.* 11(10):2574-84  
 [3] Macpherson et al. (2001) *Microbes Infect.* 3(12):1021-35  
 [4] Macpherson et al. (2002) *Cell Mol Life Sci.* 59(12):2088-96.  
 [5] Mazmanian et al. (2005) *Cell* 15;122(1):107-18.  
 [6] Frank et al. (2007) *PNAS* 104(34):13780-5.  
 45 [7] Scanlan et al. (2006) *J Clin Microbiol.* 44(11):3980-8.  
 [8] Kang et al. (2010) *Inflamm Bowel Dis.* 16(12):2034-42.  
 [9] Machiels et al. (2013) *Gut.* 63(8):1275-83.  
 [10] WO 2013/050792  
 [11] WO 03/046580  
 50 [12] WO 2013/008039  
 [13] WO 2014/167338  
 [14] Lee and Lee (2014) *World J Gastroenterol.* 20(27): 8886-8897.  
 [15] Xie et al. (2016) *Journal Dairy Sci.* 99:6913-6921  
 [16] WO 01/85187  
 55 [17] WO2016/086161  
 [18] YQ et al. (2016), *J. Dig. Dis.*, "Therapeutic Modulation of the Gut Microbiota in IBD - More Questions to Be Answered", Oct 15, 1751-2980, 12422, Epub ahead of print.  
 [19] Lozupone (2012). *Nature.* 2012 September 13; 489 (7415): 220-230

[20] Claesson, et al. (2012) *Nature*, 488, 178-184.

[21] Hansen, et al., (2010), *Curr. Opin. Gastroenterol.*, 26(6): 564-571.

[22] Turnbaugh et al. *Nature*, 457(7228): 480-484.

[23] Wang et al. (2009) *ISME J.* 3(8): 944-954.

5 [24] Faith et al. (2013), *Science*, 341(6141): 1237439

[25] Liu et al. (2008) *Int J Syst Evol Microbiol* 58, 1896-1902.

[26] Bernalier et al. (1996) *Arch. Microbiol.* 166 (3), 176-183.

[28] Måsco et al. (2003) *Systematic and Applied Microbiology*, 26:557-563.

[29] Srutková et al. (2011) *J Microbiol. Methods*, 87(1):10-6.

10 [30] Miyamoto-Shinohara et al. (2008) *J Gen. Appl. Microbiol.*, 54, 9-24.

[31] Cryopreservation and Freeze-Drying Protocols, ed. by Day and McLellan, Humana Press.

[32] Leslie et al. (1995) *Appl. Environ. Microbiol.* 61, 3592-3597.

[33] Mitropoulou et al. (2013) *J Nutr Metab.* (2013) 716861.

15 [34] Kailasapathy et al. (2002) *Curr Issues Intest Microbiol.* 3(2):39-48.

[35] Handbook of Pharmaceutical Excipients, 2nd Edition, (1994), Edited by A Wade and PJ Weller

[36] Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985)

[37] US 2016/0067188

[38] Handbook of Microbiological Media, Fourth Edition (2010) Ronald Atlas, CRC Press.

20 [39] Maintaining Cultures for Biotechnology and Industry (1996) Jennie C. Hunter-Cevera, Academic Press

[40] Strobel (2009) *Methods Mol Biol.* 581:247-61.

[41] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.

[42] Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al., eds., 1998, Academic Press).

[43] Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.)

25 [44] Handbook of Experimental Immunology, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds, 1986, Blackwell Scientific Publications)

[45] Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition (Cold Spring Harbor Laboratory Press).

[46] Handbook of Surface and Colloidal Chemistry (Birdi, K.S. ed., CRC Press, 1997)

[47] Ausubel et al. (eds) (2002) Short protocols in molecular biology, 5th edition (Current Protocols).

30 [48] PCR (Introduction to Biotechniques Series), 2nd ed. (Newton & Graham eds., 1997, Springer Verlag)

[49] Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) Supplement 30

[50] Smith & Waterman (1981) *Adv. Appl. Math.* 2: 482-489.

[51] Meyza and Blanchard (2017) *Neurosci Biobehav Rev.*;76(Pt A):99-110

[52] Constantinescu et al. (2011) *Br J Pharmacol.* 164(4):1079-1106

## 35 SEQUENCE LISTING

## [0180]

40 <110> 4D Pharma PLC

<120> COMPOSITIONS COMPRISING BACTERIAL STRAINS

<130> P069516WO

45 <141> 2017-12-12

<150> GB1621123.7

<151> 2016-12-12

50 <160> 5

<170> SeqWin2010, version 1.0

55 <210> 1

<211> 1372

<212> DNA

<213> Blautia stercoris

&lt;400&gt; 1

5	tgcaagtgcg	gcgaagcgct	tacgacagaa	ccttcggggg	aagatgtaa	ggactgagcg	60
	gcggacgggt	gagtaacgcg	tggtaacct	gcctcataca	gggggataac	agttggaaac	120
	ggctgctaat	accgcataag	cgcacggtat	cgcatac	agtgtaaaa	actccggtgg	180
	tatgagatgg	accgcgtct	gattagctag	ttggaggggt	aacggccac	caaggcgacg	240
	atcagtagcc	ggcctgagag	ggtgaacggc	cacattggga	ctgagacacg	gcccagactc	300
	ctacgggagg	cagcagtggg	gaatattgca	caatggggg	aaccctgatg	cagcgacgcc	360
	gcgtgaagga	agaagtatct	cggtatgtaa	acttctatca	gcagggaaaga	aaatgacggt	420
10	acctgactaa	gaagccccgg	ctaactacgt	gccagcagcc	gcggtaatac	gtagggggca	480
	agcgttatcc	ggatttactg	ggtgtaaagg	gagcgttagac	ggaagagcaa	gtctgtatgt	540
	aaaggctggg	gcttaacccc	aggactgcat	tggaaactgt	tttctttag	tgccggagag	600
	gtaagcggaa	ttccttagtgt	agcggtgaaa	tgcgtagata	ttaggaggaa	caccagtggc	660
	gaaggcggct	tactggacgg	taactgacgt	tgaggctcga	aagcgtgggg	agcaaacagg	720
	attagatacc	ctggtagtcc	acgcgtaaa	cgcataatac	taggtgttgg	ggagoaaagc	780
	tcttcggtgc	cgcagcaaac	gcaataagta	ttccacctgg	ggagtagcgtt	cgcaagaatg	840
	aaactcaaag	gaattgacgg	ggacccgcac	aagcgtgg	gcatacggtt	taattcgaag	900
	caacgcgaag	aaccttacca	agtcttgaca	tcgatctgac	cggttcgtaa	tggAACCTTT	960
	ctttcggac	agagaagaca	gggtgtgc	gttgcgtc	agctcgtgtc	gtgagatgtt	1020
	gggttaagtc	ccgcaacggag	cgcaacccc	atcctcagta	gccagcaggt	gaagctggc	1080
20	actctgtgga	gactgccagg	gataacctgg	aggaaggcgg	ggacgcgtc	aaatcatcat	1140
	gccccttatg	atttgggcta	cacacgtgt	acaatggcgt	aaacaaaggg	aagcgagccc	1200
	gcgagggggg	gcaaataccca	aaaataacgt	cccagttcg	actgcagtct	gcaactcgac	1260
	tgcacgaagc	tggaaatcgct	agtaatcgcg	aatcagaatg	tcgcgggtgaa	tacgtccccg	1320
	gttcttgtac	acaccgcccc	tcacaccatg	ggagtcagta	acgccccgaag	tc	1372

25

<210> 2  
 <211> 1438  
 <212> DNA  
 <213> Blautia wexlerae

30

<220>  
 <221> misc\_feature  
 <222> 19  
 <223> 'n' is a, c, g or t

35

<220>  
 <221> misc\_feature  
 <222> 19  
 <223> 'n' is a, c, g or t

40

&lt;400&gt; 2

45

50

55



5 <210> 4  
 <211> 1384  
 <212> DNA  
 <213> Artificial Sequence  
 10 <220>  
 <223> consensus 16s for Blautia wexlerae  
 15 <220>  
 <221> misc\_feature  
 <222> 749  
 <223> 'n' is a, c, g or t  
 20 <220>  
 <221> misc\_feature  
 <222> 749  
 <223> 'n' is a, c, g or t  
 25 <400> 4  
 30 ttcattgaga cttcgggtgga ttttagattct atttcttagtg gcggacgggt gagtaacgcg 60  
 tggtaacct gccttataca ggggataaac agtcagaaat ggctgctaat accgcataaag 120  
 cgcacagagc tgcgtggctc agtgtgaaaaa actccgggtg tataagatgg acccgcggtg 180  
 gattagctt gttgggtgggt aacggccac caaggcgacg atccatagcc ggcctggagag 240  
 ggttaacggc cacattggga ctgagacacg gcccagactc ctacgggagg cagcagtggg 300  
 gaatattgca caatggggga aaccctgtatg cagcgacgccc gctgtgaagga agaagtatct 360  
 cggtatgtaa acttctatca gcagggaaaga tagtgacggt acttgactaa gaagccccgg 420  
 ctaactacgt gccagcagcc gcgtaataac ttagggggca agcgttatcc ggatttactg 480  
 ggtgtaaagg gagcgttagac ggtgtggcaa gtctgtatgt aaaggcatgg gctcaacctg 540  
 35 tggactgcat tggaaaactgt catactttag tgcggaggg gtaagcggaa ttccctagtgt 600  
 agcgtgaaa tgcgtagata ttaggaggaa caccagtggc gaaggcggct tactggacgg 660  
 taactgacgt tgaggctcga aagcgtgggg agcaaaacagg attagataacc ctggtagtcc 720  
 acgcccgtaaa cgtatgaataac taggtgtcng gggagcatgg ctcttcgggtg ccgtcgcaaa 780  
 40 cgcagtaagt attccacctg gggagtacgt tcgcaagaat gaaactcaaa ggaattgacg 840  
 gggacccgca caagcggtgg agcatgtgg ttaattcgaa gcaacgcgaa gaacottacc 900  
 aagtcttgac atccgcctga ccgatcctta accggatctt tccttcggga caggogagac 960  
 aggtggtgca tgggtgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga 1020  
 gcgcaaccccc tattcctcaagt agccagcatt taaggtggc actctgggg aactgccagg 1080  
 gataacctgg aggaaggcgg ggatgacgtc aaatcatcat gccccttatg atttgggcta 1140  
 cacacgtgct acaatggcgt aaacaaagg aagcgagatc gtgagatgga gcaaattccca 1200  
 45 aaaataacgt cccagttcgg actgtatgtct gcaacccgac tacacgaagc tggaatcgct 1260  
 agtaatcgcg gatcagaatg ccgcgggtgaa tacgttcccg ggtcttgcgtac acaccgccc 1320  
 tcacaccatg ggagttagta acgcccgaag tcagtgacct aactgcaaag aaggagctgc 1380  
 50 cgaa  
 <210> 5  
 <211> 1458  
 <212> DNA  
 <213> Blautia hydrogenotrophica  
 55 <220>  
 <221> misc\_feature  
 <222> 1416  
 <223> 'n' is a, c, g or t  
 <220>  
 <221> misc\_feature  
 <222> 1416  
 <223> 'n' is a, c, g or t

&lt;400&gt; 5

5	gatgaacgct ggcggcgtgc ttaacacatg caagtcaac gaagcgata gagaacggaga 60 tttcggttga agttttctat tgactgagtg gcggacgggt gagaacgcg tggtaacct 120 gcctataca gggggataac agttagaaat gactgcta atccgcataa cgcacagctt 180 cgcatgaagc ggtgtaaaaa actgaggtgg tataggatgg acccgcgtt gattagctag 240 tttgtgaggt aacggcccac caaggcgcacg atccatagcc ggcctgagag ggtgaacggc 300 cacattggga ctgagacacg gcccaaactc ctacgggagg cagcagtggg gaatattgca 360
10	caatggggga aaccctgatg cagcgacgcc gcgtgaagga agaagtatct cggtatgtaa 420 acttctatca gcagggaaaga aagtgacggt acctgactaa gaagccccgg ctaattacgt 480 gccagcagcc gcggtaatac gtaagggca agcgttatcc ggatttactg ggtgtaaagg 540 gagcgtagac ggttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcat 600 tggaaactgt cagactttag tgccggagag gcaagcggaa ttcttagtgt agcggtaaaa 660 tgcgtagata ttaggagggaa caccagtggc gaaggcggcc tgctggacgg taactgacgt 720 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa 780 cgatgaatac taggtgtcgg gtggcaaagc cattcggtgc cgcagcaac gcaataagta 840 ttcccacctg gggagtagct tcgcaagaat gaaactcaaa ggaattgacg gggacccgca 900 caagcggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaaccttacc aaatcttgac 960 atccctctga cgggaaagta atttccctt ttcttcggaa cagaggagac aggtggcga 1020 tggtgtcgt cagtcgtgt cgtgagatgt tgggttaagt cccgcaacga ggcgaaccct 1080 tattcttagt agccagcagg tagagctggg cactctaggg agactgccaag ggataacctg 1140 gaggaaggtg gggatgacgt caaatcatca tggcccttat gatttggcgt acacacgtc 1200 tacaatggcg taaacaaagg gaagcgaagg ggtgacctgg agcaaatctc aaaaataacg 1260 tctcagttcg gattgttagtc tgcaactcga ctacatgaag ctgaaatcgc tagtaatcgc 1320 gaatcagaat gtcgcggtga atacgttccc ggtcttgta cacaccgccc gtcacaccat 1380 gggagtcagt aacgcccga gtcagtgacc caaccnaaag gaggagctg ccgaaggtgg 1440 gactgataac tgggttga 1458

30 **Claims**

1. A composition comprising a bacterial strain of the species *Blautia hydrogenotrophica*, for use in treating or preventing irritable bowel syndrome wherein the treatment or prevention comprises increasing the microbiota diversity in the subject.
2. The composition for use according to claim 1, wherein the subject has less than 99 different bacterial species and/or less than 190 different bacterial strains in its microbiota.
3. The composition for the use in any preceding claim, wherein the increase in microbiota diversity is for non-acetogenic bacteria or is for both acetogenic and non-acetogenic bacteria.
4. The composition for the use of any one of the preceding claims, wherein:
  - (a) the subject is a frail elderly subject or
  - (b) the subject is an infant who has been delivered by Caesarean section.
5. The composition for the use of any one of the preceding claims, wherein the microbiota diversity is increased in the intestine and/or in the distal gut of the subject.
6. The composition for the use of any one of claims 1-5, wherein the bacteria strain is the *Blautia hydrogenotrophica* bacterium deposited under accession number DSM 10507 and also under accession number DSM 14294.
7. The composition for the use of any preceding claim, wherein:
  - (a) the composition is for oral administration; and/or
  - (b) the composition comprises one or more pharmaceutically acceptable excipients or carriers; and/or
  - (c) the bacterial strain is lyophilised; and/or
  - (d) the bacterial strain is viable; and/or

(e) the bacterial strain is capable of partially or totally colonising the intestine.

8. The composition for the use of any preceding claim, which comprises a single strain of *Blautia hydrogenotrophica*.

5 9. The composition for the use of any preceding claim, wherein the composition comprises *Blautia hydrogenotrophica* and does not comprise bacteria from any other genus or comprises such other bacteria only in *de minimis* amounts.

10 10. The composition for the use of any preceding claim, wherein the composition comprises *Blautia hydrogenotrophica* and does not comprise bacteria from any other species or comprises such other bacteria only in *de minimis* amounts.

11. The composition for the use of any one of claims 1-7, which comprises *Blautia hydrogenotrophica* as part of a microbial consortium.

15 12. A food product comprising the composition of any preceding claim, for the use of any preceding claim.

13. A vaccine composition comprising the composition of any one of claims 1-11, for the use in any one of claims 1-11.

### Patentansprüche

20 1. Zusammensetzung, die einen Bakterienstamm der Art *Blautia hydrogenotrophica* enthält, zur Verwendung bei der Behandlung oder Vorbeugung von Reizdarmsyndrom, wobei die Behandlung oder Vorbeugung die Vergrößerung der Mikrobiotadiversität in dem Individuum umfasst.

25 2. Zusammensetzung zur Verwendung nach Anspruch 1, wobei das Individuum weniger als 99 verschiedene Bakterienarten und/oder weniger als 190 verschiedene Bakterienstämme in seiner Mikrobiota aufweist.

30 3. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die Vergrößerung der Mikrobiotadiversität nicht-acetogene Bakterien betrifft oder sowohl acetogene als auch nicht-acetogene Bakterien betrifft.

4. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei:

35 (a) das Individuum ein schwächliches älteres Individuum ist oder

(b) das Individuum ein Säugling ist, der durch Kaiserschnitt entbunden wurde.

5. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die Mikrobiotadiversität im Darm und/oder dem distalen Darm des Individuums vergrößert wird.

40 6. Zusammensetzung zur Verwendung nach einem der Ansprüche 1-5, wobei es sich bei dem Bakterienstamm um das *Blautia-hydrogenotrophica*-Bakterium handelt, das unter Zugangsnummer DSM 10507 und auch unter Zugangsnummer DSM 14294 hinterlegt ist.

7. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei:

45 (a) die Zusammensetzung zur oralen Verabreichung vorgesehen ist; und/oder

(b) die Zusammensetzung einen oder mehrere pharmazeutisch akzeptable Hilfsstoffe oder Träger umfasst; und/oder

(c) der Bakterienstamm lyophilisiert ist; und/oder

(d) der Bakterienstamm lebensfähig ist; und/oder

(e) der Bakterienstamm in der Lage ist, den Darm teilweise oder vollständig zu besiedeln.

8. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, die einen einzelnen Stamm von *Blautia hydrogenotrophica* enthält.

55 9. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die Zusammensetzung *Blautia hydrogenotrophica* enthält und keine Bakterien einer anderen Gattung enthält oder solche Bakterien nur in geringfügigen Mengen enthält.

10. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die Zusammensetzung *Blautia hydrogenotrophica* enthält und keine Bakterien einer anderen Art enthält oder solche Bakterien nur in ge-  
ringfügigen Mengen enthält.

5 11. Zusammensetzung zur Verwendung nach einem der Ansprüche 1-7, die *Blautia hydrogenotrophica* als Teil eines mikrobiellen Konsortiums enthält.

12. Lebensmittelprodukt, das die Zusammensetzung nach einem der vorhergehenden Ansprüche enthält, zur Verwen-  
dung nach einem der vorhergehenden Ansprüche.

10 13. Impfstoffzusammensetzung, die die Zusammensetzung nach einem der Ansprüche 1-11 enthält, zur Verwendung nach einem der Ansprüche 1-11.

15 **Revendications**

1. Composition comprenant une souche bactérienne de l'espèce *Blautia hydrogenotrophica*, pour une utilisation dans le traitement ou la prévention du syndrome du côlon irritable, où le traitement ou la prévention comprend l'augmen-  
tation de la diversité du microbiote chez le sujet.

20 2. Composition pour une utilisation selon la revendication 1, où le sujet possède moins de 99 espèces bactériennes différentes et/ou moins de 190 souches bactériennes différentes dans son microbiote.

25 3. Composition pour une utilisation selon l'une quelconque des revendications précédentes, où l'augmentation de la diversité du microbiote concerne les bactéries non acétogènes ou concerne les bactéries acétogènes ainsi que non acétogènes.

4. Composition pour une utilisation selon l'une quelconque des revendications précédentes, où

30 (a) le sujet est un sujet âgé fragile ; ou  
(b) le sujet est un bébé issu d'un accouchement par césarienne.

5. Composition pour une utilisation selon l'une quelconque des revendications précédentes, où la diversité du micro-  
biote est augmentée dans les intestins et/ou l'intestin distal du sujet.

35 6. Composition pour une utilisation selon l'une quelconque des revendications 1-5, où la souche bactérienne est la bactérie *Blautia hydrogenotrophica* déposée sous le numéro d'accès DSM 10507 et également sous le numéro d'accès DSM 14294.

40 7. Composition pour une utilisation selon l'une quelconque des revendications précédentes, où :  
(a) la composition est destinée à une administration orale ; et/ou  
(b) la composition comprend un ou plusieurs excipients ou véhicules pharmaceutiquement acceptables ; et/ou  
(c) la souche bactérienne est lyophilisée ; et/ou  
(d) la souche bactérienne est viable ; et/ou  
(e) la souche bactérienne est capable de coloniser partiellement ou totalement les intestins.

45 8. Composition pour une utilisation selon l'une quelconque des revendications précédentes, qui comprend une souche unique de *Blautia hydrogenotrophica*.

50 9. Composition pour une utilisation selon l'une quelconque des revendications précédentes, où la composition com-  
prend *Blautia hydrogenotrophica* et ne comprend pas de bactéries de tout autre genre ou comprend de telles autres bactéries seulement selon des quantités de *minimis*.

55 10. Composition pour une utilisation selon l'une quelconque des revendications précédentes, où la composition com-  
prend *Blautia hydrogenotrophica* et ne comprend pas de bactéries de toute autre espèce ou comprend de telles autres bactéries seulement selon des quantités de *minimis*.

11. Composition pour une utilisation selon l'une quelconque des revendications 1-7, qui comprend *Blautia hydrogenotrophica* comme partie d'un micro-organisme.
- 5 12. Produit alimentaire comprenant la composition selon l'une quelconque des revendications précédentes, pour une utilisation selon l'une quelconque des revendications précédentes.
13. Composition de vaccin comprenant la composition selon l'une quelconque des revendications 1-11, pour une utilisation selon l'une quelconque des revendications 1-11.

10

15

20

25

30


35


40

45

50

55



**FIG. 2**Shannon Diversity  
Day 16 Versus Day 1

**FIG. 3A**  
Healthy individuals








FIG. 3A1






**FIG. 3A2**  
Day\_16








**FIG. 3A3(Contd)**  
**End\_of\_Study**

**FIG. 3B**  
IBS patients



# FIG. 3B1

## Day\_1







FIG. 3B1(Contd)

Day\_1

**FIG. 3B2**  
Day\_16








FIG. 3B2(Contd)

Day\_16


**FIG. 3B3**  
**End\_of\_Study**



**FIG. 4A**Bray-Curtis Dissimilarity between  
Day 16 Versus Day 1


**FIG. 4B**

Bray-Curtis Dissimilarity  
End of Study Versus Day 1



**FIG. 4C**

Bray-Curtis Dissimilarity  
Day 16 Versus End of Study









FIG. 5


**FIG. 6A**  
Healthy individuals




**FIG. 6A1**  
Day\_1












FIG. 6A3








FIG. 6A3(Contd)




**FIG. 6A3(Contd)**



**FIG. 6B1**  
**Day\_1**







Day\_1

**FIG. 6B1(Contd)**

**FIG. 6B2**


Day\_16






**FIG. 6B2(Contd)**


Day 16






**FIG. 6B3(Contd)**  
**End\_of\_Study**


FIG. 7




**FIG. 7(Contd)**

Day 1      Day 16      End of Study







**FIG. 7(Contd)**



**FIG. 8**



**FIG. 9A**



**FIG. 9B**




FIG. 9C




FIG. 10

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 2013050792 A [0179]
- WO 03046580 A [0179]
- WO 2013008039 A [0179]
- WO 2014167338 A [0179]
- WO 0185187 A [0179]
- WO 2016086161 A [0179]
- US 20160067188 A [0179]
- GB 1621123 A [0180]

## Non-patent literature cited in the description

- **SPOR** et al. *Nat Rev Microbiol.*, 2011, vol. 9 (4), 279-90 [0179]
- **TAP** et al. *Environ Microbiol*, 2009, vol. 11 (10), 2574-84 [0179]
- **MACPHERSON** et al. *Microbes Infect.*, 2001, vol. 3 (12), 1021-35 [0179]
- **MACPHERSON** et al. *Cell Mol Life Sci.*, 2002, vol. 59 (12), 2088-96 [0179]
- **MAZMANIAN** et al. *Cell*, 2005, vol. 15;122 (1), 107-18 [0179]
- **FRANK** et al. *PNAS*, 2007, vol. 104 (34), 13780-5 [0179]
- **SCANLAN** et al. *J Clin Microbiol.*, 2006, vol. 44 (11), 3980-8 [0179]
- **KANG** et al. *Inflamm Bowel Dis.*, 2010, vol. 16 (12), 2034-42 [0179]
- **MACHIELS** et al. *Gut*, 2013, vol. 63 (8), 1275-83 [0179]
- **LEE ; LEE**. *World J Gastroenterol.*, 2014, vol. 20 (27), 8886-8897 [0179]
- **XIE** et al. *Journal Dairy Sci.*, 2016, vol. 99, 6913-6921 [0179]
- **YQ** et al. Therapeutic Modulation of the Gut Microbiota in IBD - More Questions to Be Answered. *J. Dig. Dis.*, 15 October 2016, vol. 12422, 1751-2980 [0179]
- **LOZUPONE**. *Nature*, 13 September 2012, vol. 489 (7415), 220-230 [0179]
- **CLAESSON** et al. *Nature*, 2012, vol. 488, 178-184 [0179]
- **HANSEN** et al. *Curr. Opin. Gastroenterol.*, 2010, vol. 26 (6), 564-571 [0179]
- **TURNBAUGH** et al. *Nature*, vol. 457 (7228), 480-484 [0179]
- **WANG** et al. *ISME J.*, 2009, vol. 3 (8), 944-954 [0179]
- **FAITH** et al. *Science*, 2013, vol. 341 (6141), 1237439 [0179]
- **LIU** et al. *Int J Syst Evol Microbiol*, 2008, vol. 58, 1896-1902 [0179]
- **BERNALIER** et al. *Arch. Microbiol.*, 1996, vol. 166 (3), 176-183 [0179]
- **MASCO** et al. *Systematic and Applied Microbiology*, 2003, vol. 26, 557-563 [0179]
- **SRUTKOVA** et al. *J Microbiol. Methods*, 2011, vol. 87 (1), 10-6 [0179]
- **MIYAMOTO-SHINOHARA** et al. *J Gen. Appl. Microbiol.*, 2008, vol. 54, 9-24 [0179]
- Cryopreservation and Freeze-Drying Protocols. *Humana Press* [0179]
- **LESLIE** et al. *Appl. Environ. Microbiol.*, 1995, vol. 61, 3592-3597 [0179]
- **MITROPOULOU** et al. *J Nutr Metab.*, 2013, 716861 [0179]
- **KAILASAPATHY** et al. *Curr Issues Intest Microbiol.*, 2002, vol. 3 (2), 39-48 [0179]
- Handbook of Pharmaceutical Excipients. 1994 [0179]
- Remington's Pharmaceutical Sciences. *Mack Publishing Co*, 1985 [0179]
- **RONALD ATLAS**. *Handbook of Microbiological Media*. CRC Press, 2010 [0179]
- **JENNIE C. HUNTER-CEVERA**. *Maintaining Cultures for Biotechnology and Industry*. Academic Press, 1996 [0179]
- **STROBEL**. *Methods Mol Biol.*, 2009, vol. 581, 247-61 [0179]
- **GENNARO**. *Remington: The Science and Practice of Pharmacy*. 2000 [0179]
- Molecular Biology Techniques: An Intensive Laboratory Course. Academic Press, 1998 [0179]
- Methods In Enzymology. Academic Press, Inc, [0179]
- Handbook of Experimental Immunology. *Blackwell Scientific Publications*, 1986, vol. I-IV [0179]
- **SAMBROOK** et al. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 2001 [0179]
- Handbook of Surface and Colloidal Chemistry. CRC Press, 1997 [0179]
- Short protocols in molecular biology. *Current Protocols*, 2002 [0179]

- PCR (Introduction to Biotechniques Series). Springer Verlag, 1997 [0179]
- Current Protocols in Molecular Biology. 1987 [0179]
- **SMITH ; WATERMAN.** *Adv. Appl. Math.*, 1981, vol. 2, 482-489 [0179]
- **MEYZA ; BLANCHARD.** *Neurosci Biobehav Rev.*, 2017, vol. 76, 99-110 [0179]
- **CONSTANTINESCU et al.** *Br J Pharmacol.*, 2011, vol. 164 (4), 1079-1106 [0179]